# Novel semi-automated methodology for developing highly predictive QSAR models: application for development of QSAR models for insect repellent amides 

Jayendra B. Bhonsle • Apurba K. Bhattacharjee • Raj K. Gupta

Received: 10 January 2006 / Accepted: 21 June 2006 / Published online: 20 September 2006
(C) Springer-Verlag 2006


#### Abstract

Conventional 3D-QSAR models are built using global minimum conformations or quantum-mechanics based geometry-optimized conformations as bioactive conformers. QSAR models developed using the global minima as bioactive conformers, employing the GFA, PLS and G/PLS methodologies, gave good non-validated $r^{2}(0.898,0.868$ and 0.922 ) and performed well on an internal validation test with leave-one-out correlation $q^{2}$ Loo ( $0.902,0.726$ and 0.924 ), leave- $10 \%$-out correlation $q^{2}$ L100 ( $0.874,0.728$ and 0.883 ) and leave- $20 \%$-out $q^{2}$ L200 ( $0.811,0.716$ and 0.907 ). However, they showed poor predictive ability on an external data set with best predictive $r^{2}\left(\right.$ Pred $\left.-r^{2}\right)$ of $0.349,0.139$ and 0.204 respectively. A novel methodology to mine bioactive conformers, from clusters of conformations with good 3D-spatial representation around pharmacophoric moiety, furnishes highly predictive 3DQSAR models. The best QSAR model (model A) showed $r^{2}$ of $0.989, q^{2}$ LOO of $0.989, q^{2}$ L10O of $0.980, q^{2}{ }_{\text {L20O }}$ of 0.963 and Pred $-r^{2}$ on eight test compounds of 0.845 . The methodology is based on mimicking the multi-way Partial Least Squares (PLS) technique by performing several automated sequential PLS analyses. The poses/shapes of


[^0]the mined bioactive conformers provide valuable insight into the mechanism of action of the insect repellents. All of the repetitive tasks were automated using Tcl-based Cerius2 scripts.

Keywords 3D QSAR • Insect repellents •
Bioactive conformer mining • Cerius2 scripts

## Abbreviations

| QSAR | quantitative structure-activity relationship |
| :--- | :--- |
| PLS | partial least squares |
| GFA | genetic function approximation |
| G/PLS | genetic partial least squares |
| RMS | root mean squares |
| Pred $r^{2}$ | predictive $r^{2}$ |
| LOO | leave-one-out |
| L10O | leave-10\%-out |
| L20O | leave-20\%-out |
| GPCR | G-protein coupled receptors |
| DSP | descriptor significance percentage <br> PPE |
| percentage prediction error |  |
| CtoBA | contribution to BioActivity |
| PT | protection time |
| Tcl | tool command language |
| DEET | N,N-diethyl-3-methyl benzamide <br> odorant binding protein |
| OBP | odorant degrading enzyme |
| JH | juvenile hormone |
| CoMFA | comparative molecular field analysis |
| MSA | molecular shape analysis <br> CoMSIA |
| comparative molecular similarity index |  |
| analysis |  |

HASL hypothetical active site lattice
MTD-ADJ minimal topologic difference using adjusted biological activities
SD sum of squared deviations
PRESS
$\mathrm{S}(y)$
MTI

Prediction Error Sum of Squares
standard error for the $y$ estimate minimum threshold index

## Introduction

Quantitative Structure Activity Relationships (QSAR) are among the most widely used techniques in rational drug design. Following the pioneering work of Hansch et al. [1] in 2D-QSAR, several sophisticated techniques like Comparative Molecular Field Analysis (CoMFA) [2], Molecular Shape Analysis (MSA) [3], Comparative Molecular Similarity Index Analysis (CoMSIA) [4], Condensed Phase Optimized Molecular Potentials for Atomistic Simulation Studies (COMPASS) [5], and Hypothetical Active Site Lattice (HASL) [6] have been developed for three-dimensional QSAR (3D-QSAR). Several novel two-dimensional QSAR (2D-QSAR) descriptors to quantify the topology and information-content of molecules have been reported recently. Among them are the Weiner [7], Zagreb [8], and Hosoya indices [9], the Kier and Hall molecular connectivity indices [10], the Kier and Hall subgraph count indices [10], Kier's shape indices [11], molecular flexibility indices [12], and the Balaban indices [13]. Some 2D-molecular-graph-based graph-theoretic descriptors recently reported are the information-content-info of atomic composition descriptors [14], information index based on adjacency matrix (A-matrix), distance matrix (D-matrix), Edge matrix (E-matrix) and edge-distance matrix (ED-matrix) [8], the sum of atomic polarizability [15], and the multi-graph information content indices [8]. Several novel 3D-descriptors to capture the conformational electronic and spatial information have also been reported. Among the recently reported 3D-descriptors are shadow indices [16] and Jurs indices [17]. All of the 2D and 3D-descriptors have been used widely in QSAR models. For example, in antitubercular agents [18], sulfamates have been used to distinguish sweet, sweet-bitter and bitter tasting molecules [19], and octopaminergic agonists to inhibit sex-pheromone production in insects [20].

Selection of the bioactive conformer is among the most important challenges in QSAR analysis [21]. Numerous sophisticated techniques have been reported to address this challenge, such as by Hopfinger et al. [22] using conformational averaging or conformational ensembles; by Hasagewa et al. [23] employing several conformers in multi-way data arrays; by Vedani et al. [24] using multi-
conformational ligand representation; by Appell et al. [25] invoking tensor decomposition; by Hasagewa et al. [21] employing three-way-PLS analysis; by Xiao et al. [26] propounding the Targacept Active Conformational Search algorithm; and by Sulea et al. [27] employing the multi-conformational minimal topologic difference (MTDADJ) using adjusted biological activities.

Previously, we have shown that employing several conformers of highly flexible cyclic pentapeptides in a CoMFA-based QSAR study coupled with several sequential partial least square analyses mimicking the multi-wayPartial Least Square analysis, we could develop highly predictive QSAR models [28]. In this paper we extend this method with a semi-automated heuristic using the Cerius2 software package [29] to develop highly predictive 3DQSAR models for insect repellents.

Mosquitoes transmit a variety of parasites and pathogens including those that cause malaria, yellow fever, dengue fever, filariasis and viral encephalitis [30]. Keeping the mosquitoes away using insect repellents is, therefore, a significant preventive approach against these deadly diseases. The factors involved in attracting mosquitoes to their hosts are complex and not well understood [31]. Mosquitoes have chemo-receptors on their antenna that are involved in the host-sensing mechanism [32]. Davis et al. [33] have reported that mosquitoes' chemo-receptors may be inhibited by N,N-diethyl-3-methyl benzamide (DEET). The DEET molecules in the vapor state have access to the chemosensilla and membranes in the body via the pores in the cuticle and tracheal system. The interaction of DEET molecules with the dendrite membrane lipids is thought to perturb them so that the normal response of the mosquitoes to other attractants is altered [34]. The currently reported participating entities in the mechanism of action [35] of DEET and other odorants are the odorant-binding proteins (OBPs), the G-protein-coupled receptors (GPCRs) and the odorant-degrading enzymes (ODEs). The OBPs are believed to bind to odorants that are typically hydrophobic, and facilitate their movement through the hydrophilic hemolymph to the GPCRs on the cell (neurons) surfaces. It is believed that only the OBPs and odorant complex alone can bind with the GPCRs. The ODEs prevent continued stimulation of the olfactory receptors by degrading the molecules associated with the olfactory stimulus.

Amides, both aliphatic and aromatic, are well known mosquito repellents [36, 37]. Skinner et al. [38] have studied the relationship of repellency/potency of N,N-diethyl benzamides with their boiling points, polarizabilities and partition coefficients. Other physico-chemical characteristics that are correlated with repellency/potency are lipophilicity [34], molecular size [39], and molecular shape [40]. Suryanarayana et al. [41] have reported the synthesis and mosquito
repellency testing of forty aromatic and cyclohexyl carboxylic acid amides. Further, they have also shown the structure-activity relationship of lipophilicity, molecular length and molar refractivity to repellency/potency. Ma et al. [42] studied the electronic properties of several insect repellent benzamides and benzylamides. They have demonstrated that a specific range of the van der Waals surface electrostatic potential of the amide nitrogen and oxygen atoms, and the atomic charges and dipole moments is required for the compounds to exhibit potent repellency activity. Previously, we have reported a molecular similarity analysis study of several DEET analogs and the insect juvenile hormone (JH) [43]. We have also reported observing similarity of stereoelectronic attributes such as the electrostatic potentials of the amide and/or ester moieties in the benzamides, benzylamides, JH and JH-mimic compounds and the large distribution of hydrophobic regions in these molecules. These features play a crucial role in molecular recognition between repellent compounds and JH receptors. More recently, we have reported [44] a pharmacophore for insect repellent activity using a CATALYST-based QSAR study of eleven known insect repellents. Here we illustrate the semi-automated quasi-multiway PLS methodology by building the QSAR model for forty insect repellents based on different aliphatic and aromatic amides reported by Suryanarayana et al. [41] We have also compared our results with the GFA, G/PLS and PLS based QSAR models built using global minima.

## Materials and methods

Cerius2 (C2) version 4.9 [29] running on a Silicon Graphics Octane workstation under the IRIX 6.5 operating system was used for all of the modeling work presented here. Gasteiger-Marsili [45] charges and the Dreiding 2.21 force field [46] were used for all of the computations in this study. Unless otherwise noted, default C2 settings were used.

## Data set

We used a collection of forty compounds that included benzamides, benzyl amides and cyclohexyl amide derivatives for this QSAR study. Suryanarayana et al. [41] have reported the protection time (PT) of these compounds against the mosquito species Anopheles aegypti. The PT was determined as follows. The test compound was applied at a dosage of $1 \mathrm{mg} \mathrm{cm}^{-2}$ to an alcohol cleaned human fist. The compound laced fist was then exposed to 200 female (5-7 days old) day-biting Aedes aegypti mosquitoes for five minutes. This was repeated every thirty minutes. PT is
defined as the period of protection offered until two consecutive bites are obtained in that half-hour interval. The data set was divided into a two parts: training set of thirty compounds and test set of ten compounds. The activity-ranking algorithm described by Golbraikh et al. [47] was used for training and test set selection. Table 1 summarizes the chemical structures, vapor pressure at $30^{\circ} \mathrm{C}$ and biological activity data of all the compounds.

Molecular structure building, conformational search and cluster analyses

Each structure was built using the C2 3D-sketcher and minimized. Exhaustive conformational searches were performed using the Grid Scan method [48]. The grid scan step size was selected as follows: For compounds with three or fewer torsions $30^{\circ}$ was used; for five or more torsions, $45^{\circ}$ was used; for four torsions, $45^{\circ}$ was used for bonds attached to the amidic N and $30^{\circ}$ for the rest. The torsion bond is defined as a single bond connecting different groups, which on rotation would give rise to potential localminimum conformers. Tcl-based Cerius2 scripts [49] were developed to automate the repetitive conformational searches.

We performed cluster analysis based on the RMS (root mean squares) differences of the torsion angles between the conformers. The steps in the algorithm [48] are as follows: All of the conformers are sorted by energy. The lowest energy conformer is assigned to the first cluster and it becomes the cluster nucleus. Next, all the conformers that have an RMS difference below the specified threshold value are placed in the first cluster. The lowest energy conformer of the remaining unclustered conformers is placed in the second cluster as its cluster nucleus. Again, all the conformers that have an RMS difference below the specified threshold value are placed in the second cluster. The above two steps are repeated until all the conformers are placed into clusters.

Preliminary cluster analysis was performed to generate $10-15,15-20,20-25,25-30$ and $30-35$ conformers per cluster. The nuclei of each cluster were aligned using the amide group, the common core, as the template. The hydrophobic moiety on the carbonyl side of the amide and the aliphatic side chain on the nitrogen side of the amide, of each cluster set, were examined for 3D-spatial representation. The cluster nuclei for the $10-15$ and 15-20 set showed no representative conformers in the region around the amide. Nuclei in the $25-30$ and $30-35$ conformer sets showed crowding in some region around the amide. The nuclei of the 20-25 conformer set showed good 3Dsampling with little or no vacant volume, with much less crowding or over-representation. Consequently, we chose 21-24 conformational clusters for our QSAR analysis.

Table 1 Compounds structure and bioactivity data

| Compound Structure | Compd \# | X | R1 | R2 | $\begin{aligned} & \text { PT } \\ & \text { Hrs } \end{aligned}$ | Training <br> or Test <br> Set | VP |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1a | $4-\mathrm{OCH}_{3}$ | Et | H | 0.08 | Test | 0.0062 |
|  | 1b |  | $\mathrm{CH}_{3}$ | $\mathrm{CH}_{3}$ | 1.00 | Training | 0.0039 |
|  | 1c |  | Et | Et | 1.00 | Training | 0.0037 |
|  | 1d |  | iPr | ${ }_{\text {iPr }}$ | 1.17 | Training | 0.0155 |
|  | 1e |  | $\mathrm{C}_{5} \mathrm{H}_{10}$ |  | 0.75 | Training | 0.1486 |
|  | 2 a | $4-\mathrm{CH}_{3}$ | Et | H | 0.08 | Training | 0.0063 |
|  | 2b |  | $\mathrm{CH}_{3}$ | $\mathrm{CH}_{3}$ | 4.00 | Training | 0.0110 |
|  | 2 c |  | Et | Et | 2.83 | Training | 0.0244 |
|  | 2d |  | iPr | $\mathrm{iPr}^{\text {Pr }}$ | 0.50 | Test | 0.0159 |
|  | 2 e |  | $\mathrm{C}_{5} \mathrm{H}_{10}$ |  | 1.00 | Training | 0.0313 |
|  | 3 a | H | Et | H | 0.58 | Training | 0.0015 |
|  | 3b |  | $\mathrm{CH}_{3}$ | $\mathrm{CH}_{3}$ | 1.67 | Test | 0.0015 |
|  | 3c |  | Et | Et | 4.00 | Training | 0.1015 |
|  | 3d |  | iPr | ${ }_{\mathrm{i} P r}$ | 3.00 | Training | 0.0116 |
|  | 3 e |  | $\mathrm{C}_{5} \mathrm{H}_{10}$ |  | 3.00 | Test | 0.0559 |
|  | 4a | $3-\mathrm{CH}_{3}$ | Et | H | 0.67 | Training | 0.0013 |
|  | 4b |  | $\mathrm{CH}_{3}$ | $\mathrm{CH}_{3}$ | 3.00 | Training | 0.0055 |
|  | 4 c |  | Et | Et | 5.00 | Test | 0.0260 |
|  | 4d |  | iPr | ${ }_{\mathrm{i} P r}$ | 2.67 | Test | 0.0151 |
|  | 4e |  | $\mathrm{C}_{5} \mathrm{H}_{10}$ |  | 1.42 | Training | 0.0001 |
|  | 5 a | $2-\mathrm{Cl}$ | Et | H | 0.58 | Training | 0.0006 |
|  | 5b |  | $\mathrm{CH}_{3}$ | $\mathrm{CH}_{3}$ | 5.00 | Training | 0.0076 |
|  | 5 c |  | Et | Et | 3.00 | Training | 0.0602 |
|  | 5d |  | iPr | ${ }_{\text {iPr }}$ | 1.00 | Test | 0.7728 |
|  | 5 e |  | $\mathrm{C}_{5} \mathrm{H}_{10}$ |  | 1.00 | Training | 0.0281 |
|  | 6 a | 2-OEt | Et | H | 0.08 | Training | 0.0003 |
|  | 6b |  | $\mathrm{CH}_{3}$ | $\mathrm{CH}_{3}$ | 2.83 | Training | 0.0264 |
|  | 6 c |  | Et | Et | 3.50 | Training | 0.0012 |
|  | 6d |  | iPr | ${ }_{\mathrm{i} P r}$ | 1.08 | Test | 0.0144 |
|  | 6 e |  | $\mathrm{C}_{5} \mathrm{H}_{10}$ |  | 1.33 | Training | 0.0030 |
|  | 7a |  | Et | H | 1.00 | Training | 0.0058 |
|  | 7b |  | $\mathrm{CH}_{3}$ | $\mathrm{CH}_{3}$ | 2.17 | Test | 0.0020 |
|  | 7c |  | Et | Et | 6.00 | Training | 0.1043 |
|  | 7d |  | iPr | $\mathrm{iPr}^{\text {P }}$ | 1.00 | Test | 0.0014 |
|  | 7e |  | $\mathrm{C}_{5} \mathrm{H}_{10}$ |  | 2.58 | Training | 0.1814 |
|  | 8 a |  | Et | H | 0.50 | Training | 0.0168 |
|  | 8b |  | $\mathrm{CH}_{3}$ | $\mathrm{CH}_{3}$ | 3.00 | Training | 0.0136 |
|  | 8 c |  | Et | Et | 4.00 | Training | 0.1638 |
|  | 8d |  | iPr | iPr | 2.00 | Training | 0.2843 |
|  | 8 e |  | $\mathrm{C}_{5}$ |  | 2.00 | Training | 0.0315 |

[^1]Molecular/conformational alignment, descriptor computation and QSAR model building

All conformers were aligned using the amidic carbonyl carbon, carbonyl oxygen and amide nitrogen as the common-core substructure. C2 Align was used to align the conformers. A total of 127 descriptors were computed for all of the conformers and the correlation matrix computed. PLS was used to compute the QSAR models with the descriptor column auto scaled and means removed. The number of components to explore was set to six unless otherwise noted.

GFA, G/PLS, PLS and Quasi-multi-way PLS analyses
In the genetic function approximation (GFA) method [50], QSAR models are constructed from a randomly chosen proper subset of the independent variables (descriptors) and then these models are "evolved." A generation is the set of models obtained from multiple linear regression analysis on each model. The best models selected become the next generation. Newer models are obtained by "cross-over" operations on the best models selected, which take some variables from each of the two models to produce an offspring. After the specified number of iterations, the best models are returned by the method. For this study, the GFA was used with C2 default settings, except for the following parameters: Initial equation length used was 15 , constants were added to the equation and no fixed length was set for the final equation.

The partial least squares (PLS) method [51] is used when there are far more independent variables (descriptors) than observations and when there is co-linearity in the independent variables. We used the following PLS parameters: 6 components to explore, the column means removed and the column data auto-scaled. The internal 'regression-only' cross-validation was used during the model building process.

G/PLS is a hybrid of the best features of GFA and PLS. $\mathrm{G} / \mathrm{PLS}$ is reported to give better QSAR models than GFA or PLS alone [52].

The definitions of the statistical terms used are as follows:

Equation (1) gives the conventional correlation coefficient or the non-validated correlation coefficient $r^{2}$.

$$
\begin{equation*}
r^{2}=1-\left(\left(\sum\left(Y-Y_{\text {pred }}\right)^{2}\right) /\left(\sum\left(Y-Y_{\text {mean }}\right)^{2}\right)\right) \tag{1}
\end{equation*}
$$

where $Y$ is the observed bioactivity, $Y_{\text {pred }}$ is the predicted bioactivity and $Y_{\text {mean }}$ is the mean bioactivity of all the training set compounds.

Equation (2) gives the cross-validation correlation coefficient $q^{2}$.

$$
\begin{equation*}
q^{2}=1-\left(\left(\sum\left(Y-Y_{C V \text { pred }}\right)^{2}\right) /\left(\sum\left(Y-Y_{\text {mean }}\right)^{2}\right)\right) \tag{2}
\end{equation*}
$$

where $Y_{\mathrm{CV} \text { pred }}$ is the cross-validated predicted bioactivity.
Equation (3) gives the predictive correlation coefficient $r_{\text {Pred. }}^{2}$
$r_{\text {Pred }}^{2}=(\mathrm{SD}-\mathrm{PRES}) / \mathrm{SD}$
where SD is the sum of squared deviations between the bioactivity of compounds in the test set and the mean bioactivity of the training set compounds, PRES is the sum of the squared deviation between the predicted and observed bioactivity for every test set compound.

Prediction Error Sum of Squares (PRESS) for the training set compounds is given by Eq. (4).

PRESS $=\sum\left(Y-Y_{\text {pred }}\right)^{2}$
The $F$-value or $F$-statistics is a variance-related parameter used to compare models developed using varying numbers of independent variables (descriptors). This is used to determine if a complex model (more descriptors) is significantly better than a less complex model. Equation (5) gives the $F$-value.

$$
\begin{align*}
F= & \left(\sum\left(Y_{\text {pred }}-Y_{\text {mean }}\right)^{2} / v_{1}\right) /  \tag{5}\\
& \left(\sum\left(Y-Y_{\text {pred }}\right)^{2} / v_{2}\right)
\end{align*}
$$

where $\nu_{1}$ and $\nu_{2}$ are degrees of freedom associated with the regression sum of squares (numerator, variance explained) and the residual sum of squares (denominator, variance unexplained), respectively. A confidence level of $95 \%$ ( $\alpha=0.05$ ) is generally considered significant.

The standard error for the $y$ estimate $S(y)$, is also the unexplained variance, and is given by Eq. (6).
$S(y)=\left(\sum\left(Y-Y_{\text {pred }}\right)^{2} / \nu_{2}\right)^{1 / 2}$
where $\nu_{2}$ is the number of degrees of freedom associated with the residual sum of squares.

The multi-way PLS method, developed by Bro et al. [53] was used to develop the 3D-QSAR models of insecticidal neonicotinoid compounds [54]. Each dimension of the multi-way data corresponds to the compounds in training set, CoMFA field variables, conformations and alignments. The conformers and alignments that gave the best correla-
tion to observed bioactivities were determined from the multi-way PLS solution. We have mimicked the multi-wayPLS analyses by performing several sequential two-way PLS analyses on our data. We used a Tcl based Cerius2 script [55] to automate the repetitive task of several PLS analyses.

## QSAR pharmacophore model using CATALYST

The previously reported pharmacophore model for insect repellents was generated from a training set of eleven structurally diverse arthropod repellents [44]. CATALYST [56] was used to develop the model by placing suitable constraints on the number of available chemical features, such as aromatic hydrophobic or aliphatic hydrophobic interactions, hydrogen bond donors, hydrogen bond acceptors, hydrogen bond acceptors (lipid) and ring aromatic sites, to describe the arthropod repellent activity of the compounds. Earlier reported [43] quantum chemical calculations and the stereoelectronic properties of these compounds provided guidance for the selection of these physico-chemical features. Molecules were initially mapped to the features with their predetermined conformations generated using the "fast fit" algorithm in CATALYST. A conformational energy range of 0 to $20 \mathrm{kcal} \mathrm{mol}^{-1}$ was used for developing the set of three-dimensional conformers. The Fischer randomization test was used to rule out the possibility of chance correlation models.

## Results and discussion

Data set
The collection of forty compounds was divided into two sets: thirty training-set compounds and ten test-set compounds using activity ranking [47]. All compounds were sorted based on activity (PT) into five categories as shown in Table 2.

QSAR models of the global minimum conformers based on contemporary (GFA, PLS, G/PLS) methods

Contemporary QSAR models based on the global minimum conformations of the training set were computed with 127 descriptors and the 30 descriptors selected. Descriptors were selected as relevant if they had correlation with bioactivity greater than $0.1(|r|>0.1)$ and if the cross correlation with other descriptors was not larger than 0.9 ( $|r|<0.9$ ). Table 3 summarizes the statistical details of the QSAR models.

All models (GFA, PLS and G/PLS) were apparently significant based on the internal cross-validation tests of
leave-one-out, leave-10\%-out and leave-20\%-out with $q^{2}>0.7$, and the randomization tests. The best mean random $r$ was $0.873\left(r^{2}=0.76\right)$ compared to the best nonrandom $r$ of $0.976\left(r^{2}=0.95\right)$. Despite these apparently good statistics, all models performed poorly on external validation test of ten compounds with the best predictive $r^{2}$ of 0.349 for the GFA models. The 30 -descriptor GFA model showed modest predictive power with a predictive $r^{2}$ of 0.514 .

## Conformational search and cluster analysis

All compounds were subjected to Grid Scan method of conformational search. Compounds with three or fewer torsional bonds gave less than 2,000 conformers within $20 \mathrm{kcal} \mathrm{mol}^{-1}$ energy range of their global minimum conformer. The global minimum conformer for each compound was obtained by exhaustive minimization of the lowest energy conformer. Compounds with four or more torsional bonds yielded numbers of conformers varying from 3,747 for $\mathbf{6 e}$, to 73,139 for $\mathbf{1 c}$. The C 2 cluster analysis algorithm is limited to 2,000 conformers. Thus, all compounds with 2,000 or more conformers were reprocessed using appropriate (within $10 \mathrm{kcal} \mathrm{mol}^{-1}$ of global minima) energy cutoff values. The overlay of the original conformations (i.e. before reprocessing) and the overlay of conformation obtained after reprocessing showed no significant loss of the 3D-spatial encompassment around the amide, the putative pharmacophoric moiety [42]. Table 4 summarizes the conformational search and cluster analysis data. We used Tcl-based Cerius2 scripts [49] to automate the repetitive task of conformational searches and cluster analyses.

Our novel methodology mines the 3D-encompassing conformations cluster nuclei to identify the conformer that most closely correlates with bioactivity. Further, the use of the gradual, stepwise refinement gives steady enrichment of bioactive conformers in each successive model. This allows us to identify plausible 3D-spatial requirements for bioactivity and suggests plausible mechanistic roles for various molecular moieties.

## Molecular/conformer alignment

We used C2 Align for all alignments. We aligned 940 conformers with the amide template. This necessitated dividing the task into 40 segments because of limitations in C2 Align. For each of the forty compounds, we selected all of the twenty-three to twenty-five conformers, a common conformer viz. 1a_0, and the amide template for effecting the alignment. All the aligned training set and test set compounds showed complete 3D-spatial representation

Table 2 Data set - training and test set classification

| Compound activity class | Bioactivity range (PT-hours) | Total number of compound in range | Number of compounds in training set | Compound IDs in training set | Number of compounds in test set | Compound IDs in test set |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A | 0.0-0.79 | 9 | 7 | 1e, 2a, 3a, 4a, <br> 5a, 6a, 8a | 2 | 1a, 2d |
| B | 0.8-1.10 | 8 | 5 | 1b, 1c, 2e, 5e, 7a | 3 | 5d, 6d, 7d |
| C | 1.11-2.6 | 8 | 6 | $\begin{aligned} & \text { 1d, 4e, 6e, 7e, } \\ & 8 \mathrm{~d}, 8 \mathrm{e} \end{aligned}$ | 2 | 3b, 7b |
| D | 2.61-3.0 | 8 | 6 | $\begin{aligned} & \mathbf{2 c}, \mathbf{3 d}, \mathbf{4 b}, \mathbf{5 c}, \\ & \mathbf{6 b}, \mathbf{8 b} \end{aligned}$ | 2 | 3e, 4d |
| E | 3.01-6.0 | 7 | 6 | $\begin{aligned} & \text { 2b, 3c, 5b, 6c, } \\ & 7 \mathbf{c}, 8 \mathbf{c} \end{aligned}$ | 1 | 4c |

around the hypothesized pharmacophore amide moiety in the overlaid models. Figure 1 shows the overlay of all 940 conformers, demonstrating the 3D-spatial encompassment around the amide, the putative pharmacophore moiety. We used Cerius2 scripts [57] to automate the repetitive alignment tasks.

## 3D-QSAR model development

## Descriptor computation

A total of 127 different 2D- and 3D-descriptors were calculated for all the compounds. The ADME module

Table 3 Global minimum conformers GFA, PLS and G/PLS based QSAR model's statistical data


Table 4 Conformational search and cluster analysis data

| Compd \# | Global min energy kcal $\mathrm{mol}^{-1}$ | \# Torsion bonds | \# Confs <br> within <br> 20 kcal <br> $\mathrm{mol}^{-1}$ | Energy cutoff values for reprocessing conformer files kcal $\mathrm{mol}^{-1}$ | \# Confs within the energy cutoff range | RMS (torsion) cluster analysis |  |  | \# Clusters obtained |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  | Min <br> threshold index | Max <br> threshold index | Chosen <br> threshold index |  |
| 1a | 17.6 | 4 | 6,191 | 25 | 676 | 0 | 159 | 59 | 22 |
| 1b | 58.761 | 3 | 1,575 | - | 1,575 | 0 | 180 | 50 | 23 |
| 1c | 58.603 | 5 | 73,139 | 68 | 992 | 0 | 180 | 76 | 23 |
| 1d | 39.504 | 5 | 13,713 | 49 | 142 | 0 | 180 | 63 | 23 |
| 1e | 46.226 | 3 | 1,369 | - | 1,369 | 0 | 180 | 59.7 | 24 |
| 2a | 25.429 | 3 | 1,329 | - | 1,329 | 17 | 180 | 65.58 | 22 |
| 2b | 38.243 | 2 | 144 | - | 144 | 0 | 180 | 46 | 24 |
| 2c | 41.461 | 4 | 7,678 | 51 | 1,721 | 0 | 180 | 60 | 24 |
| 2d | 49.357 | 4 | 5,528 | 60 | 466 | 0 | 180 | 55.37 | 23 |
| 2e | 44.875 | 2 | 131 | - | 131 | 20 | 180 | 46 | 21 |
| 3a | 23.067 | 3 | 1,329 | - | 1,329 | 17 | 180 | 66.86 | 22 |
| 3b | 35.885 | 2 | 144 | - | 144 | 21 | 180 | 43 | 22 |
| 3c | 38.805 | 4 | 7,754 | 48 | 1,433 | 0 | 180 | 66.3 | 21 |
| 3d | 47.001 | 4 | 5,529 | 57 | 367 | 0 | 180 | 56.8 | 21 |
| 3e | 44.201 | 2 | 130 | - | 130 | 0 | 180 | 43.69 | 21 |
| 4a | 25.746 | 3 | 1,334 | - | 1,334 | 17 | 180 | 67 | 22 |
| 4b | 38.415 | 2 | 144 | - | 144 | 0 | 180 | 45.85 | 22 |
| 4c | 41.311 | 4 | 7,706 | 51 | 1,640 | 0 | 180 | 69.2 | 22 |
| 4d | 49.44 | 4 | 5,520 | 59 | 322 | 0 | 180 | 46.15 | 24 |
| 4e | 46.747 | 2 | 132 | - | 132 | 0 | 180 | 44.05 | 21 |
| 5a | 26.516 | 3 | 1,293 | - | 1,293 | 17 | 180 | 61.87 | 24 |
| 5b | 37.274 | 2 | 135 | - | 135 | 21 | 180 | 45 | 24 |
| 5c | 39.433 | 4 | 5,938 | 49 | 1,106 | 0 | 180 | 60 | 23 |
| 5d | 47.68 | 4 | 4,330 | 65 | 1,508 | 0 | 180 | 65 | 21 |
| 5e | 50.8 | 2 | 135 | - | 135 | 20 | 180 | 45 | 22 |
| 6 a | 28.44 | 5 | 14,607 | 38 | 1,904 | 0 | 180 | 69 | 24 |
| 6b | 39.852 | 4 | 5,898 | 49 | 1,073 | 0 | 180 | 66 | 21 |
| 6c | 42.259 | 6 | 19,837 | 52 | 1,272 | 0 | 180 | 78 | 21 |
| 6d | 50.351 | 6 | 8,674 | 60 | 207 | 0 | 180 | 55 | 22 |
| 6 e | 47.64 | 4 | 3,747 | 57 | 740 | 0 | 180 | 60 | 24 |
| 7 a | 18.964 | 4 | 6,490 | 27 | 1,910 | 0 | 180 | 60 | 24 |
| 7b | 30.089 | 3 | 1,532 | - | 1,532 | 16 | 174 | 65 | 24 |
| 7c | 32.245 | 5 | 2,0320 | 42 | 1,805 | 0 | 180 | 80 | 23 |
| 7d | 40.337 | 5 | 13,258 | 50 | 199 | 0 | 180 | 55 | 22 |
| 7 e | 37.351 | 3 | 1,289 | - | 1,289 | 16 | 180 | 62 | 21 |
| 8a | 18.667 | 3 | 1,273 | - | 1,273 | 16 | 180 | 62 | 21 |
| 8b | 29.784 | 2 | 144 | - | 144 | 21 | 180 | 45 | 22 |
| 8c | 32.599 | 4 | 5,872 | 43 | 702 | 0 | 180 | 60 | 23 |
| 8d | 43.155 | 4 | 3,972 | 62.5 | 1,832 | 0 | 180 | 65 | 23 |
| 8 e | 40.03 | 2 | 144 | - | 144 | 20 | 180 | 45 | 23 |

provides the seven ADME descriptors, polar surface area (ADME_PSA_2D), intestinal absorption values as a multivariate distance (T2) from the center of the polar surface area (PSA) - ellipse surface (ADME_Absorption_T2_2D), $\log \mathrm{P}$ values calculated based on the Ghosh and Crippen atom-types [58, 59] (ADME_AlogP68), blood-brain barrier ratios (ADME_BBB_2D), the
corresponding blood-brain barrier penetration level (ADME_BBB_level_2D), aqueous solubility at $25{ }^{\circ} \mathrm{C}$ (ADME_Solubility) and aqueous solubility ranking (ADME_Solubility_level). The Electrotopological State Descriptors (E-state) included in this study are $\mathrm{S}_{-} \mathrm{sCH} 3$, S_ssCH2, S_aaCH, S_sssCH, S_dssC, S_aasC, S_ssNH, S_sssN, S_dO, S_ssO and S_sCl. The meaning of the


Fig. 1 Overlay of all 940 conformers showing the alignment
E-state symbol S_xxx is that it is the sum of type of $x x x$, where ' $x$ ' can be ' $s$ ': single bond, ' $d$ ': double bond, ' $t$ ': triple bond and ' $a$ ': aromatic bond. (For example, S_aasC stands for the sum descriptor for carbon with two aromatic bonds and one single bond). The values for atomic E-state indices are described by Kier et al. [60] The thermodynamic descriptors included are $n$-octanol/water partition coefficient (LogP), the desolvation free energy for water (Fh2o), the desolvation free energy for $n$-octanol (Foct), the partition coefficient computed on atom types reported by Ghosh et al. [58, 59] (AlogP and AlogP98), the molar refractivity (MR) computed based on refractive index, molecular weight, compound density and the molar refractivity (MolRef) computed based on the atom-types with additive contributions reported by Ghosh et al. [58, 59] The nine Ghosh and Crippen atom type descriptors, Atype_C_1, Atype_C_2, Atype_C_5, Atype_C_6, Atype_C_24, Atype_C_25, Atype_H_46, Atype_H_47 and Atype_H_52 are counts of atom types reported by Ghose et al. $[58,59]$ The descriptor JX is the Balaban index [13], which is evaluated by taking into account the bond orders, heteroatom electronegativities and covalent radii. The Kier's shape indices included in this study are Kappa-1, Kappa-2, Kappa-3, Kappa-1-AM, Kappa-2-AM and Kappa-3-AM. These indices capture different aspects of molecular shape by comparing the molecular graph with minimal and maximal graphs [11]. The last three indices are refinements of the first three by taking into account the covalent radii and hybridization states [61].

A total of fifty-five different 3D-descriptors were calculated for all the conformers. The thirty Jurs descriptors
based on partial charges mapped onto the surface area were reported by Stanton et al. [17] The descriptors included are as follows:
a) The total molecular solvent accessible surface (JursSASA).
b) The sum of the solvent-accessible surface area of all partially positively charged atoms (Jurs-PPSA-1).
c) The sum of the solvent-accessible surface area of all partially negatively charged atoms (Jurs-PNSA-1).
d) The difference (Jurs-DPSA-1) between the partial positive solvent accessible area (PPSA-1) and partial negative solvent accessible surface area (PNSA-1).
e) The partial positive solvent-accessible surface area times the total positive charge (Jurs-PPSA-2).
f) The partial negative solvent-accessible surface area times the total negative charge (Jurs-PNSA-2).
g) The difference (Jurs-DPSA-2) between Jurs-PPSA-2 and Jurs-PNSA-2.
h) The sum of the products of solvent accessible surface area and partial charge for all positively charged atoms (Jurs-PPSA-3).
i) The sum of the products of solvent accessible surface areas and partial charge for all negatively charged atoms (Jurs-PNSA-3).
j) The difference (Jurs-DPSA-3) between Jurs-PPSA-3 and Jurs-PNSA-3.
$\mathrm{k}-\mathrm{p}$ ) These six descriptors are the fractionally charged surface areas, Jurs-FPSA-1, Jurs-FNSA-1, Jurs-FPSA-2, Jurs-FNSA-2, Jurs-FPSA-3 and Jurs-FNSA-3, which are obtained by dividing each of the descriptor PPSA-1, PNSA-1, PPSA-2, PNA-2, PPSA-3 and PNSA-3 by total molecular solventaccessible surface area (SASA) respectively.
$\mathrm{q}-\mathrm{v}$ ) These six descriptors are the surface-weighted charged partial surface areas, Jurs-WPSA-1, Jurs-WNSA-1, Jurs-WPSA-2, Jurs-WNSA-2, Jurs-WPSA-3 and Jurs-WNSA-3, which are obtained by multiplying each of the descriptors PPSA-1, PNSA-1, PPSA-2, PNSA-2, PPSA-3 and PNSA-3 by SASA and dividing by 1,000 respectively.
w) The Jurs-RPCG descriptor is the relative positive charge computed by dividing the charge of the most positive atom by the total positive charge.
x) The Jurs-RNCG descriptor is the relative negative charge computed by dividing the charge of the most negative atom by the total negative charge.
y) The Jurs-RPCS descriptor is the relative positive charge surface area, which is computed as the solvent-accessible surface area of the most positive atom divided by RPCG.
z) The Jurs-RNCS descriptor is the relative negative charge surface area, which is obtained by dividing

Table 5 List of descriptors with correlation of less than 0.1 with Bioactivity (BA)

| Descriptor | Abs(BA) |
| :---: | :---: |
| ADME_AlogP98 | 0.00722 |
| ADME_Solubility | 0.01544 |
| AlogP98 | 0.00722 |
| Area | 0.02170 |
| Atype_C_1 | 0.02218 |
| Atype_C_2 | 0.00378 |
| Atype_C_24 | 0.01618 |
| Atype_C_25 | 0.00829 |
| CHI-3_C | 0.02531 |
| CHI-3_P | 0.03172 |
| CHI-V-0 | 0.02719 |
| CHI-V-1 | 0.03795 |
| CHI-V-2 | 0.03881 |
| CHI-V-3_C | 0.02744 |
| Dipole-mag | 0.02350 |
| IC | 0.01588 |
| Jurs-PPSA-1 | 0.00020 |
| MolRef | 0.03867 |
| PHI | 0.01783 |
| Rotlbonds | 0.01565 |
| S_aaCH | 0.00869 |
| S_sCl | 0.03094 |
| S_ssCH2 | 0.02771 |
| SC-3_C | 0.01202 |
| Shadow-XZ | 0.01320 |
| Shadow-XZfrac | 0.00400 |
| Shadow-Ylength | 0.03485 |
| SIC | 0.02293 |
| Vm | 0.03713 |
| Vap Press @ $30{ }^{\circ} \mathrm{C}$ | 0.06720 |
| AlogP | 0.05078 |
| Apol | 0.07722 |
| Atype_C_6 | 0.09263 |
| Atype_H_46 | 0.06029 |
| Atype_H_52 | 0.09255 |
| BIC | 0.04456 |
| CHI-0 | 0.07652 |
| CHI-V-3_P | 0.04719 |
| CIC | 0.04263 |
| HOMO | 0.04317 |
| HOMO_MOPAC | 0.04508 |
| IAC-Total | 0.09304 |
| Jurs-DPSA-1 | 0.05433 |
| Jurs-RNCS | 0.03958 |
| Jurs-SASA | 0.08612 |
| Jurs-WPSA-1 | 0.04565 |
| Kappa-1 | 0.06079 |
| Kарра-1-AM | 0.04699 |
| Kappa-2 | 0.08430 |
| Kappa-2-AM | 0.06206 |
| LogP | 0.05800 |
| MR | 0.09360 |
| S_dO | 0.04796 |
| S_sCH3 | 0.05810 |
| S_sssCH | 0.07320 |

Table 5 (continued)

| Descriptor | Abs(BA) |
| :--- | :---: |
|  |  |
| SC-3_P | 0.08261 |
| Shadow-XYfrac | 0.04764 |
| Shadow-YZfrac | 0.07132 |
| Sr | 0.04534 |

the solvent-accessible surface area of the most negative atom divided by RNCG.
aa) The Jurs-TASA descriptors is the total hydrophobic surface area, which is computed as the sum of the solvent-accessible surface area of atoms with absolute partial charge less than 0.2.
ab) The Jurs-TPSA descriptor is the total polar surface area, which is the sum of the solvent-accessible surface areas of atom with absolute partial charges greater than or equal 0.2.
ac) The Jurs-RASA descriptor is the relative hydrophobic surface area, which is computed as the TASA divided by SASA.
ad) The Jurs-RPSA descriptor is the relative polar surface area, which is obtained by dividing TPSA by SASA.

The ten shadow indices are based on the surface area of molecular projections on the $\mathrm{XY}, \mathrm{YZ}$ and XZ planes, as reported by Rohrbaugh et al. [16] The descriptors shadowXY , shadow- YZ and shadow-XZ are areas of the molecular shadow in the $\mathrm{XY}, \mathrm{YZ}$ and XZ planes, respectively. The descriptors shadow-Xlength, shadow-Ylength and shadowZlength are the lengths of the molecule in $\mathrm{X}, \mathrm{Y}$ and Z dimensions, respectively. The descriptors shadow-XYfrac, shadow-YZfrac and shadow-XZfrac are fractions of the area of molecular shadows in the XY, YZ and XZ planes on the areas of the enclosing rectangles, respectively. The areas of molecular shadows are the appropriate products of X-length, Y-length and Z-length of the molecular shadows. The descriptor shadow-nu is the ratio of the largest to the smallest dimension. The four quantum-mechanical descriptors included are HOMO_MOPAC, LUMO_MOPAC, DIPOLE_MOPAC and HF_MOPAC. These are the HO MO, LUMO, dipole moment and heat of formation calculated by semiempirical methods, which are generally known to provide more accurate values. The 3D-spatial descriptors are Density and PMI-mag. The descriptor Density is defined as the ratio of molecular weight to molecular volume. The descriptor PMI-Mag is the magnitude of the principal moments of inertia about the principal axes of the conformers as described by Hill [62]. The descriptor Hf is a thermodynamic descriptor that gives the enthalpy of formation of the conformer as described by Dewar et al. [63] The conformational descriptor 'Energy' gives the energy of the conformer.

## Descriptor selection

The selection of descriptors is an important first step in a QSAR study. A good correlation between the selected variables and the bioactivity implies better bioactivity predictions [64]. Several techniques for descriptor selection, to reduce dimensionality, have been reported recently. L'Heureux et al. [65]. have employed local linear embedding techniques, Olah et al. [66] demonstrated the use of automated PLS search for biologically relevant descriptors, Sutter et al. [67] used a generalized simulated annealing algorithm in a computational neural network for automated descriptor selection and Zheng et al. [68] have demonstrated the use of the $k$-nearest neighbor principle for descriptor selection. We adapted the descriptor selection strategy reported earlier by Yao et al. [69] First, all descriptors that had very low correlations with the bioactivity ( $|r|<\sim 0.1$ ) were discarded. Next, the highly collinear descriptors (|cross correlation coefficient|>~0.9) were identified. Those descriptors with more physical significance to offer mechanistic insight into the QSAR information were retained. For example, given a choice between Jurs-DPSA-2, CHI-1, E-DIST-mag, SC-0, Weiner and Zagreb, the Jurs-DPSA-2 was retained because it provides information about the difference between the positively and negatively charged solvent-accessible surface areas.

The cross correlation matrix was computed. The descriptors that showed very poor correlation with bioactivity $(r<0.1)$ were removed. Table 5 shows the 59 descriptors discarded and their correlation coefficients with bioactivity.

The cross correlation matrix showed that 38 of the remaining 68 descriptors exhibited very high cross correlation ( $|r|>\sim 0.9$ ). Table 6 summarizes the descriptor types, names and their cross-correlation coefficient values. These 38 descriptors were removed to leave the following 30 final descriptors, which are presented in nine descriptor categories:
(1) ADME descriptors: ADME_Solubility_level, ADME_BBB_2D, ADME_BBB_level_2D and ADME_Absorption_T2_2D;
(2) E-state descriptors: S_dssC, S_ssO, S_aasC and S_ssNH;
(3) Graph theory based descriptors: Kappa-3-AM;
(4) Jurs descriptors: Jurs-DPSA-2, Jurs-DPSA-3, Jurs-FPSA-1, Jurs-FPSA-3, Jurs-FNSA-2, Jurs-RPCS and Jurs-RASA;
(5) Shadow index descriptors: Shadow-XY, Shadow-nu, Shadow-Xlength and Shadow-Zlength;
(6) Quantum mechanical and Electronic descriptors: LUMO_MOPAC, Hf_MOPAC and DIPOLE_ MOPAC;
(7) Conformational descriptors: Energy;
(8) 3D spatial descriptor: Density and PMI-mag; and
(9) Miscellaneous descriptors: JX, Fh2o, Atype_C_5 and Atype_H_47.

## Quasi-multi-way PLS analyses

Bhonsle et al. [28] have reported the use of automated quasi-multi-way PLS analyses for CoMFA-based 3DQSAR of cyclic pentapeptides CXCR4 inhibitors. They have mimicked multi-way-PLS analyses by employing several automated two-way-PLS analyses using the SYBYL [70] software. We have used a similar approach here. The PLS analysis procedure in C2 provides for a quick cross-validation of QSAR models. In this crossvalidation procedure, only the "regression" part of the model development is cross-validated. This "regressiononly" cross-validation was computed for all QSAR models generated. The non-validated $r^{2}$ and the sum of squares of predicted residuals (PRESS) were used to guide successive generations of model development. The conventional method of selecting conformers (or conversely outliers) is based on absolute residual values. This method gives an unfair advantage to the low activity compounds vis-à-vis the high activity ones. Thus, to remove this bias, we have coined the term 'Percentage Prediction Error (PPE)'. The PPE is computed as follows:

$$
\begin{aligned}
\text { PPE }= & \text { absolute value }(\text { Bioactivity }- \text { Predicted_Bioactivity }) \\
& * 100 / \text { Bioactivity }
\end{aligned}
$$

The selection of conformers for all generations of QSAR models was based on the PPE values.

The first generation QSAR model was obtained by performing a PLS analysis on 706 conformers of the thirty training set compounds. The number of conformers for each training-set compound is the number of clusters plus the global minimum conformer (see Table 4). The computed QSAR model showed a non-validated $r^{2}$ of 0.883 and sum of squares of predicted residuals (PRESS) of 200.06. The second (IInd) generation model of 501 conformers was obtained as follows. The predicted residual values of several conformers of the same compound in the first generation model showed almost identical values. A closer examination of the descriptor values of all such conformers showed that they were also almost identical. Thus, all such 'duplicate' conformers were removed. The computed QSAR model showed a non-validated $r^{2}$ of 0.879 and PRESS value of 135.01 . Figure 2 shows the plot of actual versus predicted bioactivity for IInd generation QSAR model.

Table 6 Highly correlated $(|r|>\sim 0.9)$ descriptors and their cross correlation coefficients

| Descriptors and cross correlation coefficients |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 | Jurs-PPSA-2 |
|  | 0.92 | 0.958 | 0.986 | 0.901 | 0.849 |
|  | Jurs-WPSA-3 | $\log \mathrm{Z}$ | MW | PMI-mag | SC-0 |
|  | 0.921 | 0.994 | 0.954 | 0.871 | 0.991 |
|  | V-DIST-mag | Wiener | Zagreb | Jurs-RNCG | Jurs-TASA |
|  | 0.984 | 0.984 | 0.977 | -0.848 | 0.889 |
|  | SC-1 | SC-2 | V-ADJ-mag | Jurs-WPSA-2 |  |
|  | 0.992 | 0.958 | 0.991 | 0.879 |  |
| CHI-2 | CHI-1 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 | Jurs-TASA |
|  | 0.92 | 0.983 | 0.939 | 0.863 | 0.876 |
|  | SC-0 | SC-1 | SC-2 | V-ADJ-mag | V-DIST-mag |
|  | 0.954 | 0.94 | 0.982 | 0.94 | 0.956 |
|  | Jurs-WPSA-2 | $\log \mathrm{Z}$ | MW | Wiener | Zagreb |
|  | 0.847 | 0.903 | 0.925 | 0.941 | 0.97 |
| E-ADJ-mag | CHI-1 | CHI-2 | E-DIST-mag | Jurs-DPSA-2 | Jurs-TASA |
|  | 0.958 | 0.983 | 0.976 | 0.855 | 0.898 |
|  | PMI-mag | SC-0 | SC-1 | SC-2 | V-ADJ-mag |
|  | 0.85 | 0.973 | 0.978 | 1 | 0.978 |
|  | Jurs-WPSA-2 | $\log \mathrm{Z}$ | MW | V-DIST-mag | Wiener |
|  | 0.845 | 0.954 | 0.95 | 0.97 | 0.957 |
|  | Zagreb |  |  |  |  |
|  | 0.996 |  |  |  |  |
| E-DIST-mag | CHI-1 | CHI-2 | E-ADJ-mag | Jurs-DPSA-2 | Jurs-TASA |
|  | 0.986 | 0.939 | 0.976 | 0.872 | 0.884 |
|  | MW | PMI-mag | SC-0 | SC-1 | SC-2 |
|  | 0.941 | 0.862 | 0.978 | 0.996 | 0.975 |
|  | Zagreb | Jurs-WPSA-2 | Jurs-WPSA-3 | $\log \mathrm{Z}$ | V-ADJ-mag |
|  | 0.989 | 0.857 | 0.888 | 0.99 | 0.997 |
|  | V-DIST-mag | Wiener |  |  |  |
|  | 0.977 | 0.976 |  |  |  |
| Jurs-DPSA-2 | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-FPSA-2 |
|  | 0.901 | 0.863 | 0.855 | 0.872 | 0.936 |
|  | Jurs-RPCG | Jurs-TASA | Jurs-WPSA-2 | Jurs-WPSA-3 | $\log \mathrm{Z}$ |
|  | -0.866 | 0.849 | 0.986 | 0.955 | 0.867 |
|  | SC-2 | V-ADJ-mag | V-DIST-mag | Wiener | Zagreb |
|  | 0.853 | 0.872 | 0.925 | 0.925 | 0.865 |
|  | Jurs-PPSA-2 | Jurs-PPSA-3 | Jurs-RNCG | SC-1 | SC-0 |
|  | 0.976 | 0.874 | -0.937 | 0.872 | 0.918 |
| Jurs-PPSA-2 | Jurs-WPSA-3 | Jurs-DPSA-2 | Jurs-FPSA-2 | Jurs-RNCG | Jurs-RPCG |
|  | 0.91602 | 0.97551 | 0.98663 | -0.924 | -0.87832 |
|  | SC-0 | V-DIST-mag | Wiener | Jurs-TASA | Jurs-WPSA-2 |
|  | 0.86272 | 0.86833 | 0.86111 | 0.86197 | 0.9952 |
| Jurs-RNCG | Jurs-WPSA-3 | Jurs-DPSA-2 | Jurs-FPSA-2 | Jurs-PPSA-2 | Jurs-PPSA-3 |
|  | -0.92241 | -0.9367 | -0.9045 | -0.924 | -0.87995 |
|  | SC-0 | V-DIST-mag | Wiener | Jurs-RPCG | Jurs-WPSA-2 |
|  | -0.85604 | -0.85231 | -0.84985 | 0.89619 | -0.92139 |
| Jurs-RPCG | Jurs-DPSA-2 | Jurs-FPSA-2 | Jurs-PPSA-2 | Jurs-PPSA-3 | Jurs-RNCG |
|  | -0.86588 | -0.89565 | -0.87832 | -0.88167 | 0.89619 |
|  | Jurs-WPSA-2 | Jurs-WPSA-3 | Kappa-3-AM |  |  |
|  | -0.85497 | -0.86542 | -0.87115 |  |  |
| Jurs-TASA | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Wiener |
|  | 0.88929 | 0.87557 | 0.89766 | 0.88447 | 0.86703 |
|  | $\log \mathrm{Z}$ | MW | SC-0 | SC-1 | SC-2 |
|  | 0.88591 | 0.8583 | 0.8954 | 0.89832 | 0.9 |
|  | Zagreb | V-DIST-mag | Jurs-WPSA-2 | Jurs-WPSA-3 | V-ADJ-mag |
|  | 0.90406 | 0.88069 | 0.87719 | 0.84887 | 0.89641 |

Table 6 (continued)
Descriptors and cross correlation coefficients

| Jurs-WPSA-2 | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | 0.87864 | 0.84707 | 0.84519 | 0.85731 | 0.98641 |
|  | Jurs-RPCG | Jurs-TASA | Jurs-WPSA-3 | $\log \mathrm{Z}$ | SC-0 |
|  | -0.85497 | 0.87719 | 0.93093 | 0.84862 | 0.89487 |
|  | Wiener | Zagreb | Jurs-FPSA-2 | Jurs-PPSA-2 | Jurs-RNCG |
|  | 0.89622 | 0.85268 | 0.9663 | 0.9952 | -0.92139 |
|  | SC-1 | V-ADJ-mag | V-DIST-mag |  |  |
|  | 0.85563 | 0.85629 | 0.90211 |  |  |
| Jurs-WPSA-3 | CHI-1 | E-DIST-mag | Jurs-DPSA-2 | Jurs-FPSA-2 | Jurs-PPSA-2 |
|  | 0.92055 | 0.88814 | 0.95471 | 0.86693 | 0.91602 |
|  | Jurs-TASA | Jurs-WPSA-2 | $\log \mathrm{Z}$ | PMI-mag | SC-0 |
|  | 0.84887 | 0.93093 | 0.9046 | 0.84588 | 0.90874 |
|  | Wiener | Zagreb | Jurs-PPSA-3 | Jurs-RNCG | Jurs-RPCG |
|  | 0.92032 | 0.8628 | 0.96366 | -0.92241 | -0.86542 |
|  | SC-1 | V-ADJ-mag | V-DIST-mag |  |  |
|  | 0.89301 | 0.89272 | 0.90388 |  |  |
| $\boldsymbol{\operatorname { l o g }} \mathrm{Z}$ | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.99398 | 0.90294 | 0.95359 | 0.98971 | 0.86659 |
|  | MW | PMI-mag | SC-0 | SC-1 | SC-2 |
|  | 0.93493 | 0.87162 | 0.97427 | 0.99493 | 0.95414 |
|  | Zagreb | Jurs-TASA | Jurs-WPSA-2 | Jurs-WPSA-3 | V-ADJ-mag |
|  | 0.97557 | 0.88591 | 0.84862 | 0.9046 | 0.9946 |
|  | V-DIST-mag | Wiener |  |  |  |
|  | 0.96398 | 0.96688 |  |  |  |
| MW | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.95364 | 0.9255 | 0.95012 | 0.94069 | 0.84938 |
|  | SC-1 | SC-2 | V-ADJ-mag | V-DIST-mag | Wiener |
|  | 0.94614 | 0.95038 | 0.94553 | 0.96351 | 0.94636 |
|  | Jurs-TASA | $\log \mathrm{Z}$ | SC-0 | Zagreb |  |
|  | 0.8583 | 0.93493 | 0.9675 | 0.95367 |  |
| PMI-mag | CHI-1 | E-ADJ-mag | E-DIST-mag | Jurs-WPSA-3 | $\log \mathrm{Z}$ |
|  | 0.87081 | 0.85008 | 0.86244 | 0.84588 | 0.87162 |
|  | SC-2 | V-ADJ-mag | V-DIST-mag | Wiener | Zagreb |
|  | 0.8503 | 0.87084 | 0.85115 | 0.87987 | 0.86331 |
|  | RadOfGyration | SC-0 | SC-1 |  |  |
|  | 0.90049 | 0.86366 | 0.87152 |  |  |
| SC-0 | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.99114 | 0.95426 | 0.9731 | 0.97755 | 0.91846 |
|  | Jurs-WPSA-2 | Jurs-WPSA-3 | $\log \mathrm{Z}$ | MW | PMI-mag |
|  | 0.89487 | 0.90874 | 0.97427 | 0.9675 | 0.86366 |
|  | V-DIST-mag | Wiener | Zagreb | Jurs-PPSA-2 | Jurs-RNCG |
|  | 0.99572 | 0.99084 | 0.98206 | 0.86272 | -0.85604 |
|  | SC-1 | SC-2 | V-ADJ-mag | Jurs-TASA |  |
|  | 0.98253 | 0.97317 | 0.98213 | 0.8954 |  |
| SC-1 | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.99154 | 0.93997 | 0.978 | 0.99595 | 0.87168 |
|  | $\log \mathrm{Z}$ | MW | PMI-mag | SC-0 | SC-2 |
|  | 0.99493 | 0.94614 | 0.87152 | 0.98253 | 0.97827 |
|  | Zagreb | Jurs-TASA | Jurs-WPSA-2 | Jurs-WPSA-3 | V-ADJ-mag |
|  | 0.99216 | 0.89832 | 0.85563 | 0.89301 | 0.99988 |
|  | V-DIST-mag | Wiener |  |  |  |
|  | 0.97441 | 0.9728 |  |  |  |
| SC-2 | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.95827 | 0.98214 | 0.99985 | 0.97515 | 0.85291 |
|  | PMI-mag | SC-0 | SC-1 | V-ADJ-mag | V-DIST-mag |
|  | 0.8503 | 0.97317 | 0.97827 | 0.97826 | 0.96855 |

Table 6 (continued)
Descriptors and cross correlation coefficients

| V-ADJ-mag | Jurs-TASA | $\log \mathrm{Z}$ | MW | Wiener | Zagreb |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | 0.9 | 0.95414 | 0.95038 | 0.95559 | 0.99651 |
|  | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.99112 | 0.94037 | 0.97823 | 0.99721 | 0.87212 |
|  | $\log \mathrm{Z}$ | MW | PMI-mag | SC-0 | SC-1 |
|  | 0.9946 | 0.94553 | 0.87084 | 0.98213 | 0.99988 |
|  | Zagreb | Jurs-TASA | Jurs-WPSA-2 | Jurs-WPSA-3 | SC-2 |
|  | 0.9921 | 0.89641 | 0.85629 | 0.89272 | 0.97826 |
|  | V-DIST-mag | Wiener |  |  |  |
|  | 0.97532 | 0.97391 |  |  |  |
| V-DIST-mag | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.98351 | 0.95572 | 0.96989 | 0.97724 | 0.92468 |
|  | Jurs-WPSA-2 | Jurs-WPSA-3 | $\log \mathrm{Z}$ | MW | PMI-mag |
|  | 0.90211 | 0.90388 | 0.96398 | 0.96351 | 0.85115 |
|  | V-ADJ-mag | Wiener | Zagreb | Jurs-PPSA-2 | Jurs-RNCG |
|  | 0.97532 | 0.99485 | 0.976 | 0.86833 | -0.85231 |
|  | Jurs-TASA | SC-0 | SC-1 | SC-2 |  |
|  | 0.88069 | 0.99572 | 0.97441 | 0.96855 |  |
| Wiener | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.98425 | 0.9412 | 0.95714 | 0.97623 | 0.92535 |
|  | Jurs-WPSA-2 | Jurs-WPSA-3 | $\log \mathrm{Z}$ | MW | PMI-mag |
|  | 0.89622 | 0.92032 | 0.96688 | 0.94636 | 0.87987 |
|  | V-ADJ-mag | V-DIST-mag | Zagreb | Jurs-PPSA-2 | Jurs-RNCG |
|  | 0.97391 | 0.99485 | 0.96754 | 0.86111 | -0.84985 |
|  | Jurs-TASA | SC-0 | SC-1 | SC-2 |  |
|  | 0.86703 | 0.99084 | 0.9728 | 0.95559 |  |
| Zagreb | CHI-1 | CHI-2 | E-ADJ-mag | E-DIST-mag | Jurs-DPSA-2 |
|  | 0.97669 | 0.97034 | 0.99632 | 0.98865 | 0.86495 |
|  | $\log \mathrm{Z}$ | MW | PMI-mag | SC-0 | SC-1 |
|  | 0.97557 | 0.95367 | 0.86331 | 0.98206 | 0.99216 |
|  | Wiener | Jurs-TASA | Jurs-WPSA-2 | Jurs-WPSA-3 | SC-2 |
|  | 0.96754 | 0.90406 | 0.85268 | 0.8628 | 0.99651 |
|  | V-ADJ-mag | V-DIST-mag |  |  |  |
|  | 0.9921 | 0.976 |  |  |  |
| ADME_PSA_2D | Fh2o | Foct | Fh2o | ADME_PSA_2D | Foct |
|  | -0.922 | -0.885 |  | -0.922 | 0.902 |
| Jurs-WNSA-3 | Jurs-DPSA-3 | Jurs-PNSA-2 | Jurs-PNSA-3 | Jurs-WNSA-1 | Jurs-WNSA-2 |
|  | -0.9275 | 0.91715 | 0.88193 | -0.85335 | 0.89103 |
| Jurs-RPSA | Jurs-RASA | Jurs-TPSA | Jurs-WNSA-2 | Jurs-DPSA-3 | Jurs-PNSA-2 |
|  | -1 | 0.94917 |  | -0.84799 | 0.96571 |
| Jurs-FPSA-2 | Jurs-DPSA-2 | Jurs-PPSA-2 | Jurs-RNCG | Jurs-RPCG | Jurs-WPSA-2 |
|  | 0.9361 | 0.98663 | -0.9045 | -0.89565 | 0.9663 |
| Jurs-PNSA-2 | Jurs-DPSA-2 | Jurs-PPSA-2 | Jurs-RNCG | Jurs-RPCG | Jurs-WPSA-2 |
|  | 0.9361 | 0.98663 | -0.9045 | -0.89565 | 0.9663 |
| Jurs-PNSA-3 | Jurs-FNSA-2 | Jurs-FNSA-3 | Jurs-WNSA-3 | LUMO | LUMO_MOPAC |
|  | 0.87575 | 0.87464 | 0.88193 |  | 0.94779 |
| Jurs-DPSA-3 | Jurs-PNSA-2 | Jurs-WNSA-2 | Jurs-WNSA-3 | LUMO_ MOPAC | LUMO |
|  | -0.847 | -0.848 | -0.928 |  | 0.94779 |
| Jurs-FNSA-1 | Jurs-FNSA-3 | Jurs-FPSA-1 | Jurs-PNSA-1 | S_sssN | S_ssNH |
|  | -0.85712 | -1 | 0.92642 |  | -0.98072 |
| Jurs-FNSA-3 | Jurs-FNSA-1 | Jurs-FPSA-1 | Jurs-PNSA-3 | S_ssNH | S_sssN |
|  | -0.85712 | 0.85712 | 0.87464 |  | -0.98072 |
| Jurs-FPSA-1 | Jurs-FNSA-1 | Jurs-FNSA-3 | Jurs-PNSA-1 | HF_MOPAC | Hf |
|  | -1 | 0.85712 | -0.92642 |  | 0.9664 |
| Shadow-YZ | Shadow-Zlength | Shadow-Zlength | Shadow-YZ | Hf | HF_MOPAC |
|  | 0.87557 |  | 0.87557 |  | 0.966 |

Table 6 (continued)

| Descriptors and cross correlation coefficients |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Jurs-RASA | Jurs-RPSA | Jurs-TPSA | RadOf Gyration | PMI-mag | Shadow-Xlength <br>  <br> Jurs-TPSA |
|  | -1 | -0.94917 |  | 0.90049 | ADME_PSA_2D |
| Jurs-FNSA-2 | Jurs-RASA | Jurs-WPSA-3 | Foct | Fh2o |  |
|  | -0.94917 | 0.86693 |  | -0.885 | 0.902 |
|  | Jurs-PNSA-1 | Jurs-RPSA | Kappa-3-AM | Jurs-RPCG | Kappa-3 |
| Jurs-PNSA-1 | -0.91545 | 0.94917 |  | -0.87115 | 0.94634 |
|  | Jurs-FNSA-1 | Jurs-PNSA-2 | Jurs-PNSA-3 | Jurs-WNSA-1 |  |
| Jurs-WNSA-1 | 0.92642 | 0.92624 | 0.87575 | -0.94703 | Jurs-WNSA-1 |
|  | Jurs-FNSA-2 | Jurs-FNSA-2 | Jurs-FPSA-1 | 0.9098 |  |
| Jurs-PPSA-3 | -0.94703 | -0.91545 | -0.92642 | Jurs-WNSA-3 |  |
|  | Jurs-DPSA-2 | Jurs-PNSA-1 | Jurs-PNSA-2 | -0.85335 |  |
| Kappa-3 | 0.8736 | 0.9098 | -0.93312 | Jurs-WPSA-3 |  |
|  | Kappa-3-AM | Jurs-RNCG | Jurs-RPCG | 0.96366 |  |
|  | 0.94634 | -0.87995 | -0.88167 |  |  |

## Selection of best, worst and moderate performing conformers approach

In the quasi-multi-way PLS analyses approach reported by Bhonsle et al. [28] the two least residual value conformers were selected for the intermediate QSAR model, followed by the selection of the least residual value conformer for the final QSAR model. Thus, our first attempt was to try selecting six conformers of each compound, such that two would have the least residual values, two with the worst residual values and two with the mean or median residual values. The idea behind this approach is that the PLS regression analysis will have the complete gamut of the descriptor values to be able to create a broadly predictive QSAR model. The third (IIIrd) generation model had 180 conformers with $r^{2}$ of 0.885 and PRESS of 57.52. The fourth (IVth) generation model obtained by selecting three conformers for each compound, with best residual value, worst residual value and the mean or median residual value. This model of 90 conformers showed $r^{2}$ of 0.881 and PRESS of 36.55 . Two fifth (Vth) generation models of 60 conformers were obtained using the following two approaches. In the first approach, conformers showing the best and the worst residual values were selected to give a model with $r^{2}$ of 0.852 and PRESS of 46.50. In the second approach, conformers showing the best and the mean or median residual values were selected to give a model with $r^{2}$ of 0.934 and PRESS of 22.77. The final or sixth (VIth) generation models from the above two approaches were obtained by selecting one conformer for every compound with the best residual values. Both of these models, with 30 conformers, showed poor internal validation (leave-oneout regression-only cross-validation) correlation coefficient values. The model built via the first approach gave nonvalidated $r^{2}$ of 0.896 and $q^{2}$ LOO of 0.450 . While, the model obtained from the second approach showed non-validated $r^{2}$ of 0.873 and $q^{2}$ LOO of 0.415 .

## Stepwise, gradual, worst residual value conformer elimination $r^{2}$ and PRESS-guided conformer selection approach

Since the steep approach of selecting the best, worst and moderate performing conformers failed to provide a good QSAR model, we tried a more gentle approach. We eliminated the worst residual value conformer in a stepwise and gradual fashion. We used the nonvalidated $r^{2}$ and PRESS as measures to guide the model improvement.

The IIIrd generation model of 300 conformers was obtained by selecting 10 least PPE values conformers and it showed a non-validated $r^{2}$ of 0.921 and PRESS value of 60.43 . The IVth generation model of 150 conformers was constructed with the five least residual value conformers from the IIIrd generation model. This model displayed a non-validated $r^{2}$ of 0.965 and PRESS value of 15.12 . The Vth generation model of 60 conformers was obtained with two least residual value conformers and it exhibited non-validated $r^{2}$ of 0.988 and PRESS value of 3.10 . The VIth generation model was constructed by eliminating the worst residual value conformers of all compounds with PT less than 3.0. For the remaining nine compounds, $\mathbf{2 b}$ (4.0), $\mathbf{3 c}(4.0), \mathbf{3 d}(3.0), \mathbf{5 b}$ (5.0), 5c (3.0), $\mathbf{6 c}(3.50), 7 \mathrm{c}(6.0), \mathbf{8 b}(3.0)$ and $\mathbf{8 c}(4.0)$, two conformers each were retained in the model. This QSAR model had non-validated $r^{2}$ of 0.991 and PRESS value of 2.565. At this juncture, there were 18 conformers from which the best set of nine conformers could be chosen in $512\left(2^{9}\right)$ ways. We used a Tcl-based Cerius2 script [55] to compute these 512 seventh (VIIth) generation models. We found six models with leave-one-out (regression-only) cross-validated $r^{2}$ of 0.67 or larger. The best VIIth generation QSAR model showed a non-validated $r^{2}$ of 0.989 , leave-one-out (regres-sion-only) cross-validated $r^{2}$ of 0.701 and PRESS value of 20.37. Figure 3 shows the best final QSAR model.

## IInd Generation 501 rows model



Actual Bioactivity
Fig. 2 Second-generation QSAR model with 501 conformers
The statistical data of the six QSAR models selected (Models A-F) with the selected conformer number of the nine compounds $\mathbf{2 b}, \mathbf{3 c}, \mathbf{3 d}, 5 \mathrm{~b}, 5 \mathrm{c}, \mathbf{6 c}, \mathbf{7 c}, \mathbf{8 b}$ and $\mathbf{8 c}$ is shown in Table 7. The statistical data and selected conformer numbers for QSAR model G built using the original pool of 127 descriptors are also included in Table 7. It is noteworthy that in the six models selected all but four $(\mathbf{2 b}, \mathbf{5 b}, \mathbf{6 c}$ and $\mathbf{8 c})$

## VIIth Generation QSAR Model A



Fig. 3 Best QSAR Model A of thirty training set compounds
compounds have the same conformer numbers. The overlay of the conformers of compounds $\mathbf{2 b}, \mathbf{5 b}, \mathbf{6 c}$ and $\mathbf{8 c}$ show that the substitutions on the amidic N are spatially very close to each other. A representative overlay of conformer 8c_0 and 8 c _ 5 is shown in Fig. 4c.

The statistical data of all the seven generation models obtained during the QSAR model development phases are shown in Table 8.

Table 7 Statistical data of selected 30 descriptors six (A-F) models and 127 descriptors (G) Model

| Model\# | Conformer \# of 21 compounds common to all six(A-F) Models | Conformer \# selected for the 9 active/very active compounds | $\begin{aligned} & \mathrm{NV} \\ & r^{2} \end{aligned}$ | Leave-one-out (regression only) crossvalidated |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | $q^{2}$ | PRESS |
| A | 1b_21; 1c_6; 1d_18; 1e_24; 2a_11; 2c_3; 2e_16; 3a_0; 4a_0; 4b_2; 4e_12; 5a_16; 5e_4; 6a_1; 6b_7; 6e_4; 7a_22; 7e_5; 8a_5; 8d_5; 8e_23 | $\begin{aligned} & \text { 2b_13; 3c_15; 3d_6; 5b_1; } \\ & \text { 5c_5; 6c_4;7c_15; 8b_14; } \\ & \text { 8c_5 } \end{aligned}$ | 0.989 | 0.701 | 20.37 |
| B |  | $\begin{aligned} & \text { 2b_13; 3c_15; 3d_6; 5b_22; } \\ & \text { 5c_5; 6c_16; 7c_15; 8b_14; } \\ & 8 \mathrm{c} \_5 \end{aligned}$ | 0.988 | 0.674 | 22.2 |
| C |  | $\begin{aligned} & \text { 2b_13; 3c_15; 3d_6; 5b_22; } \\ & \text { 5c_5; 6c_16; 7c_15; 8b_14; } \\ & \text { 8c_0 } \end{aligned}$ | 0.991 | 0.673 | 22.28 |
| D |  | ```2b_13; 3c_15; 3d_6; 5b_1; 5c_5; 6c_16; 7c_15; 8b_14; 8c_5``` | 0.989 | 0.674 | 22.21 |
| E |  | ```2b_13; 3c_15; 3d_6; 5b_1; 5c_5; 6c_16; 7c_15; 8b_14; 8c_0``` | 0.991 | 0.673 | 22.29 |
| F |  | ```2b_7; 3c_15; 3d_6; 5b_22; 5c_5; 6c_16; 7c_15; 8b_14; 8c_5``` | 0.988 | 0.674 | 22.24 |
| G |  | $\begin{aligned} & \text { 4a_14; 4b_9; 4e_17; 5a_4; 5b_2; } \\ & \text { 8c_3; 8d_1;8e_12 } \end{aligned}$ | 0.984 | 0.719 | 19.12 |

Fig. 4 a) IIIrd Generation

8c Conformers. b) IVth Generation 8c Conformers. c) Vth Generation 8c Conformers

a)

The final best QSAR model A with the selected conformers, predicted bioactivities and percent prediction errors is shown in Table 9.

It is noteworthy that QSAR Model A predicts all (thirteen) of the potent $(\mathrm{PT}>2.5 \mathrm{~h})$ insect repellents within a PPE of $14 \%$. Of these thirteen compounds, eleven are within a PPE of $10 \%$ and nine, quite accurately, within a PPE of $3 \%$. The algorithm used for discovering the bioactive conformers, leading to QSAR models A-F is summarized in Fig. 5.

## The QSAR models/equations

## Bioactive conformer mining and insights <br> into the mechanism of action

The gradual and stepwise refinement of successive generation QSAR models by selecting the least PPE (residual) value conformers affords the conformers that correlate best with the observed bioactivity. Thus, these selected conformers are the bioactive conformations of the respective compounds. On examination of the ten, five and two selected conformers in the IIIrd, IVth and Vth generation models respectively, we find that our novel methodology selects the cluster of

Table 8 Statistical data of all generation QSAR models

| QSAR <br> model <br> generation <br> number | Number of <br> Conformers <br> in model | Non- <br> validated <br> $r^{2}$ | Leave-one-out <br> cross-validated <br> (regression only) | PRESS |
| :--- | :--- | :--- | :--- | :--- |
| 1 |  |  | q2 |  |
| 2 | 706 | 0.883 | 0.877 | 200.06 |
| 3 | 501 | 0.879 | 0.869 | 135.01 |
| 4 | 300 | 0.921 | 0.911 | 60.43 |
| 5 | 150 | 0.965 | 0.956 | 15.12 |
| 6 | 60 | 0.988 | 0.977 | 3.10 |
| 7 | 39 | 0.991 | 0.974 | 2.565 |



Table 9 Best QSAR Model A selected conformers predicted bioactivities and percent prediction errors

| Compound_Conformer | Actual <br> bioactivity | Model \# <br> A <br> predicted <br> bioactivity | Percent error in <br> model A <br> predicted <br> bioactivity=abs <br> (BA-PredBA) |
| :--- | :--- | :--- | :--- |
|  |  |  | *100/BA |

bioactive conformers and further refines the cluster over successive generations, finally to yield the best bioactivity correlating conformer. This phenomenon is illustrated in Figs. 4, 6, 7 and 8. Figure 4 shows the IIIrd, IVth and Vth generation selected conformers of compound $8 \mathbf{c}(\mathrm{PT}=4)$ of activity class E. The same observations are also shown for compound $\mathbf{3 d}(\mathrm{PT}=3)$ ) of activity class D in Fig. 6 and for compound $\mathbf{8 d}(\mathrm{PT}=2)$ of activity class C in Fig. 7.

Figure 8a-c show the overlay of selected conformers for the VIIth generation model A of all compounds of the high activity classes $\mathrm{C}, \mathrm{D}$ and E , respectively.

As is evident from Figs. 4, 6, 7 and 8 that the $\alpha$-to-amide $\mathrm{C}-\mathrm{N}$ bonds ' a ' ' $b$ ' and ' $c$ ' ' $d$ ' (see Fig. 9) form a cluster within a 60 degree range (e.g. Figs. $4 a, 6 a$ and $7 a$ ) and the
cluster is enriched with the bioactive conformers with narrower angle ranges for bonds 'a' ' $b$ ' and ' $c$ ' ' $d$ ' (e.g. see Figs. $4 \mathrm{~b}, 6 \mathrm{~b}, 7 \mathrm{~b}$ and $4 \mathrm{c}, 6 \mathrm{c}, 7 \mathrm{c}$ ) over the successive QSAR model generations.

The shapes of the selected conformers over the successive generations also allude to the roles of various moieties around the putative amide pharmacophore in the mechanism of action and the structure activity relationship. Closer study of the cluster of conformers in the successive generation models, their shapes around the amide group and their PPE values gave the following observations.
i) The 3D-spatial location of the phenyl, benzyl or cyclohexyl moiety attached to the carbonyl C does not have any significant effect on the bioactivity.

Fig. 5 Flow chart of algorithm for QSAR model development

## Flow Chart of Algorithm for QSAR model development

1. Build \& minimize Structures.
2. Grid Scan Conformational Search.
3. Cluster Conformations on RMS of torsions to get 22-24 clusters. Select the cluster Nuclei as representative conformer.
4. Compute 2D \& 3D descriptors.
5. Perform Cross Correlation Analysis of the descriptors.
6. Remove descriptors with less than 0.1 correlations to bioactivity. Remove descriptors having greater than 0.9 cross correlation.
7. Perform PLS analysis and Compute PPE to get $1^{\text {st }}$ Generation Model.
8. Examine conformers with identical PPE values. If descriptor values are nearly identical, remove theses duplicate conformers.
9. (i) Perform PLS \& compute PPE to get $2^{\text {nd }}$ Generation Model.
(ii) Sort Conformers for each compound based on PPE.
(iii) Select 10 conformers for each compound with the least PPE value.
10. (i) Perform PLS \& compute PPE to get $3^{\text {rd }}$ Generation Model.
(ii) Sort Conformers for each compound based on PPE.
(iii) Select 5 conformers for each compound with the least PPE value. Remove the other 5 conformers.
11. (i) Perform PLS \& compute PPE to get $4^{\text {th }}$ Generation Model.
(ii) Sort Conformers for each compound based on PPE.
(iii) Select 2 conformers for each compound with the least PPE value. Remove the other 3 conformers.
12. (i) Perform PLS \& compute PPE to get $5^{\text {th }}$ Generation Model.
(ii) Sort Conformers for each compound based on PPE.
(iii) For 21 compounds with PT <3.00, select the least PPE conformer. For 9 compounds with $\mathrm{PT}>3.00$, keep both the conformers.
13. (i) Perform automated PLS analysis on $2^{9}=512$ models obtained by selecting each combination of the conformer of the 9 compounds.
(ii) Select those QSAR Models which have $\mathrm{q}^{2}$ Loo $>0.67$
14. (i) Validate the QSAR Models with external test set.
(ii) Validate the QSAR Models with Fischer Randomization Test.

Fig. 6 a) IIIrd Generation 3d Conformers. b) IVth Generation 3d Conformers. c) Vth Generation 3d Conformers
ii) The bioactive conformers of all compounds show preferential positioning of the methyl, ethyl, isopropyl etc. moieties on the amidic N within a range of 60 to 70 degrees. (See Figs. 4c, 6c, 7c and 8c) Thus, the shape on the amidic N side of the molecule is critical for bioactivity.
iii) The narrower the PPE of the conformers, the closer are the $\alpha$-to-amide C-N bonds ' $a$ ', 'b' and 'c', 'd' (see Fig. 9) to each other. For example, for compound 8c (PT=4) (PPE $0.65 \%-7.4 \%$ ) see Fig. $4 a-c$. Thus, suggesting that particular 3D-spatial location of alkyl and cycloalkyl groups on the nitrogen are important for bioactivity.
The elementary requirement for the odorant to possess insect repellency is that it has a high enough vapor pressure for a significant number of molecules to reach the anthropods. Suryanarayana et al. [41] and Johnson et al. [71] reported that odorants with too low or too high vapor pressures than DEET (4c) exhibit poor PT. The mechanism of action of odorants on anthropods is reported to comprise three steps [35], which are detailed as follows. The first step is that of the odorant (Od) binding to the lipophilic odorant binding

protein (OBP). The complex (Od-OBP) then binds with the G-coupled protein receptor (GPCR) on the neuron cells in the second step, giving rise to the repellency action. In the third step, the Od-OBP degrading protein (ODP) degrades the Od-OBP complex to prevent continued stimulus to the neurons. Our SAR observations indicate that the second and third steps could compete. Thus if the Od-OBP complex is not strong enough or if the Od-OBP complex cannot bind/ dock effectively with the GPCR, then ODP would degrade the Odorant faster than the Od-OBP complex binding to the GPCR, thus resulting in poor PT.

The OBPs are usually about 20 kDa in size and comprise a single peptide with six characteristic highly conserved cysteine residues and hydrophobic domain residues between residues numbers 40 and 60 [72,74]. The hydrophobic region of the compounds is primarily on the carbonyl side of the amide. We believe that the phenyl, benzyl and cyclohexyl moieties attached to the carbonyl group dock with the OBPs between residues 40 and 60 . This step being the first step in the mechanism of action is important in the

Fig. 7 a) IIIrd Generation 8d Conformers. b) IVth Generation 8d Conformers. c) Vth Generation 8d Conformers

a)

b)


Fig. 8 a) QSAR Model A Activity class C Conformers (1.11<PT<2.6). b) QSAR Model A Activity class D Conformers ( $2.61<\mathrm{PT}<3.0$ ). c) QSAR Model A Activity class E Conformers (3.01<PT<6.0)


c)
overall SAR. Thus, compounds that do not have sufficient hydrophobic groups on the carbonyl side would show poor activity. The SAR observations supporting this theory are as follows. All five para-methoxy phenyl compounds, four of the five ortho-ethoxy phenyl compounds and three of the five ortho-chloro phenyl compounds exhibit PTs less than 3.0 h . The fact that $\mathbf{5 b}$ and $\mathbf{5 c}$ show PT of 3.0 h or larger indicates that smaller sized ortho polar substituents are tolerable for the hydrophobic pocket of the OBP.

The second step in the mechanism of action is the binding of the Od-OBP complex to the GPCR on the neuron cells. We suggest that the alkyl and cycloalkyl moieties on the amidic N probably interact with the GPCR and that this, being the crucial step for repellency, would be the 'rate determining step' in the mechanism of action. Thus, any compound that does not have favorable substitution on the amidic nitrogen in terms of 3D-spatial and physico-chemical requirements would exhibit poor PT. For example, disubstitution at the amidic N is crucial for bioactivity, thus all Xa (monosubstituted ethylamine) compounds consistently exhibit poor PTs of 0.05 to 1.0 h . Further, all diisopropyl and cyclohexyl substituted amides (except $\mathbf{3 c}$ and $\mathbf{3 d}$ ) exhibit poor PT (PT<3.0). All diethyl and


Fig. $9 \alpha$-to-amide $\mathrm{C}-\mathrm{N}$ bonds
dimethyl substituted amides (except 1b, 1c, 3b and 7b) exhibit PT higher than 2.83 with six out of twelve exhibiting PT larger than 4.0 h . The poor PT of $\mathbf{1 b}$ and $\mathbf{1 c}$ have already been explained as they, probably, bind poorly with OBP in the first step, while the poor PT of $\mathbf{3 b}$ and $\mathbf{7 b}$ could be attributed to poor vapor pressures at $30{ }^{\circ} \mathrm{C}$ of 0.0015 and 0.0020 , respectively (DEET VP @ $30^{\circ} \mathrm{C}=0.026$ ).

## QSAR equation analysis

The best QSAR model A is described by the following equation:

PLS Predicted Bioactivity $=0.53848 *$
$A D M E \_$Absorption_T2_2D-0.682301 $* A D M E \_B B B_{-}$
$2 D-0.689156 * A D M E \_B B B \_$Level_2D $-1.20977 *$
ADME_Solubility_Level - $0.04213 *$ Energy - 0.531331*
$S \_d s s C-0.192429 * S_{-}$aas $C-0.367471 * S_{-s s N H}+$
$0.054425 * S$ _ss $O+0.00082393 *$ LUMO_MOPAC +
0.432683 * DIPOLE_MOPAC $+0.0041452 *$
$H F \_M O P A C-0.00016215 *$ Jurs $-D P S A-2-$
$0.014325 *$ Jurs - DPSA $-3+1.28755 *$ Jurs - FPSA -
$1+0.530519 *$ Jurs $-F N S A-2+66.4923 *$ Jurs -
FPSA- $3+0.536246 *$ Jurs - RPCS $+12.5082 *$ Jurs -
RASA -0.008205 *Shadow-XY -0.530922 *Shadow-
$n u-0.285412 *$ Shadow-Xlength $-0.05695 *$ Shadow -
Zlength $+0.311959 *$ Density $-0.0013471 *$ PMI-
mag $-0.074066 *$ Atype_C_5 $+0.195987 *$ Atype_H_
$47+0.097114 * F h 2 o+1.5147 * J X+1.29936 *$
Kарра-3-AM - 12.4913

The values and signs of the QSAR equation coefficients provide a qualitative insight into the correlation of the physicochemical properties with biological activity. The quantitative contribution of any physicochemical property
to the bioactivity of the compound is judged from both its QSAR equation coefficient and the value of the descriptor quantifying the property. The product of the QSAR coefficients and the descriptor mean value
$\left(\right.$ Descriptor_Mean $=\sum$ Descriptor_values_all_training_set_compounds $\left./ 30\right)$
would provide the contribution value of that descriptor to the overall bioactivity (Contribution_to_BioActivity CtoBA).

CtoBA $=$ QSAR_Coefficient $*$ Descriptor_mean_value

The significance of CtoBA of any descriptor vis-à-vis the CtoBA of all the other descriptors can be computed by dividing the individual CtoBA by the sum total of all the

CtoBA of all descriptors. The percentage value of this quotient is termed as 'Descriptor Significance Percentage DSP'.
$\mathrm{DSP}=(\mathrm{CtoBA} * 100) / \sum \mathrm{abs}(\mathrm{CtoBA})$

The DSP values would provide a better insight in the quantitative contributions of the descriptors to the bioactivities of the compounds. The QSAR coefficients for the

Table 10 Computation of Descriptor Significance Percentage (DSP) for Model A

| Descriptor | QEC | MVD | CtoBA | DSP |
| :---: | :---: | :---: | :---: | :---: |
| Jurs-RASA | 12.508 | 0.882 | 11.028 | 25.038 |
| Jurs-FPSA-3 | 66.492 | 0.074 | 4.916 | 11.161 |
| JX | 1.515 | 2.527 | 3.828 | 8.690 |
| ADME_Solubility_Level | -1.210 | 3.100 | -3.750 | -8.514 |
| Shadow-Xlength | -0.285 | 11.888 | -3.393 | -7.703 |
| Kappa-3-AM | 1.299 | 2.568 | 3.337 | 7.577 |
| Energy | -0.042 | 51.357 | -2.164 | -4.912 |
| Atype_H_47 | 0.196 | 7.933 | 1.555 | 3.530 |
| DIPOLE_MOPAC | 0.433 | 3.553 | 1.537 | 3.490 |
| ADME_Absorption_T2_2D | 0.538 | 2.736 | 1.473 | 3.344 |
| Shadow-nu | -0.531 | 1.909 | -1.014 | -2.301 |
| Jurs-FPSA-1 | 1.288 | 0.770 | 0.992 | 2.252 |
| ADME_BBB_Level_2D | -0.689 | 1.300 | -0.896 | -2.034 |
| Jurs-DPSA-3 | -0.014 | 50.052 | -0.717 | -1.628 |
| Shadow-XY | -0.008 | 59.513 | -0.488 | -1.109 |
| Fh2o | 0.097 | -4.866 | -0.473 | -1.073 |
| PMI-mag | -0.001 | 324.800 | -0.438 | -0.993 |
| Shadow-Zlength | -0.057 | 6.306 | -0.359 | -0.815 |
| Density | 0.312 | 1.004 | 0.313 | 0.711 |
| Jurs-RPCS | 0.536 | 0.488 | 0.262 | 0.595 |
| S_ssNH | -0.367 | 0.642 | -0.236 | -0.536 |
| Jurs-FNSA-2 | 0.531 | -0.438 | -0.232 | -0.528 |
| S_aasC | -0.192 | 1.148 | -0.221 | -0.501 |
| Jurs-DPSA-2 | 0.000 | 808.217 | -0.131 | -0.298 |
| S_ssO | 0.054 | 1.394 | 0.076 | 0.172 |
| ADME_BBB_2D | -0.682 | 0.103 | -0.071 | -0.160 |
| S_dssC | -0.531 | 0.114 | -0.061 | -0.138 |
| HF_MOPAC | 0.004 | -11.390 | -0.047 | -0.107 |
| Atype_C5 | -0.074 | 0.533 | -0.040 | -0.090 |
| LUMO_MOPAC | 0.001 | 0.094 | 0.000 | 0.000 |

[^2]QSAR model A, CtoBA and DSP values are shown in Table 10.

The largest contribution to the bioactivity is from the descriptor Jurs-RASA (Jurs-Relative Hydrophobic Surface Area) with a value of $25 \%$ and with a positive effect. JursRASA is defined as the ratio between the total hydrophobic surface area (Jurs-TASA) and the total solvent accessible surface area (Jurs-SASA). Thus, molecules with larger hydrophobic surface area and smaller total solvent-accessible area would exhibit high potency. This observation is consistent with the first step in the mechanism of action of the molecules binding to the OBP, where hydrophobicity/ lipophilicity plays a key role. The other QSAR model A coefficients that support the role of hydrophobicity in the mechanism of action are ADME_Solubility_Level with a negative contribution of $8.5 \%$, Atype_H_47 with a positive contribution of $3.5 \%$ and Fh 20 with a negative contribution of $1.1 \%$. These observations agree with the observations of McIver et al. [34] and Suryanarayana et al. [41] that lipophilicity is directly related to repellency. The CATA-LYST-based pharmacophore model [44] is also consistent with this observation because potent insect repellents require three hydrophobic sites in the molecules for activity.

The next largest contribution to the bioactivity is from the descriptor Jurs-FPSA-3 (Jurs-Fractional Positive Surface Area 3) with a value of $11 \%$ and a positive effect. Jurs-FPSA-3 is the quotient of the Jurs PPSA-3 and Jurs-SASA. Jurs-PPSA-3 (Jurs-Partial Positive Surface Area 3) is the summation of the products of solvent-accessible surface area and partial charge of all positively charged atoms. Thus, QSAR model A indicates that molecules with larger partial positive surface areas and larger partial positive charges along with smaller total solvent accessible surface areas would show high activity. This probably refers to the second step in the mechanism of action where the odorantOBP complex binds to the neuron GPCR; where the partial positively charged amidic N of the odorant molecules is involved in hydrogen bonding with the GPCR peptide residues. The diffuse or soft positively charged moiety's contribution towards bioactivity is also supported by the following QSAR model A coefficients. Jurs-FPSA-1 (JursFractional Positive Surface Areas-1), defined as the sum of the solvent-accessible area of all partial positively charged atoms, has a positive contribution of $2.3 \%$. The Balaban index JX, which is inversely proportional to the electronegativities and covalent radii of the atoms in the repellent molecules, shows a positive contribution of $8.7 \%$. JursRPCS (Jurs-Relative Positively Charged Surface Area) and Jurs-FNSA-2 (Jurs-Fractional Negatively Charged Surface Areas-2) exhibit positive $0.6 \%$ and negative $0.5 \%$ contributions, respectively. The importance of soft positively charged moieties, optimal atomic charges and dipole moments has been reported by Ma et al. [42] in their
electrostatic potential studies of DEET analogs. The contribution of appropriate partial positive and negative charge separation in the QSAR model A is evident in the coefficients DIPOLE_MOPAC with a positive $3.5 \%$ contribution and Jurs-DPSA-3 (Jurs-Differential Partial Positive Solvent-accessible Surface Area-3) with a negative $1.6 \%$ contribution. The optimal values of dipole moment for the compounds would be relevant in both the first step of odorant-OBP complex formation and in the second odorant-OBP complex binding to the neuron GPCR.

The fifth largest DSP contribution to the QSAR model A is from Shadow-Xlength, which is the projection measure of the repellent compound on the $x$-axis, with a negative $7.7 \%$ contribution. The contributions of other shadow indices to the QSAR model A are as follows: ShadowZlength (projection measure on the $z$-axis) negative $0.8 \%$, Shadow-XY (the area of the shadow of the molecule in the XY plane) negative $1.1 \%$ and Shadow-nu (ratio of the largest to the smallest shadow measures) negative $2.3 \%$. This combination of shadow indices indicates that molecules with an elongated rectangular box (parallelepiped)like structure would be more potent than other shapes. This also alludes to the shape of the binding pocket of the OBP involved in the first step of the mechanism of action. The other significant QSAR model A coefficients that contribute to this observation are as follows. Kappa-3-AM, which is directly proportional to the number of vertices and inversely proportional to the number of edges in the molecular graph, has larger values for larger but denser molecules. Kappa-3-AM has a positive $7.6 \%$ contribution. Density (molecular density) has a positive contribution of $0.7 \%$, while PMI-mag (Principal moment of inertia magnitude) has a negative $0.99 \%$ contribution. These observations also agree with those of Suryanarayana et al. [41] and Wright et al. [40] that molecular size and shape have a large effect on repellency activity. Further, the pharmacophore reported by Bhattacharjee et al. [44] also has a parallelepiped (rectangular) shape with the aliphatic hydrophobic moiety at one end, the aromatic hydrophobic moiety at the other end and the hydrogen bond acceptor moiety around the central portion of the parallelepiped. A closer study of the shapes of the conformers selected for the QSAR model A, which correlate best with the observed bioactivities, gave the following observations. The molecular shape on the amidic nitrogen side of the molecule is more critical to the bioactivity than the carbonyl side of the amidic moiety. Thus, compounds with a piperidine moiety like $\mathbf{1 e}, \mathbf{2 e}, \mathbf{3 e}$ etc. consistently exhibit poor ( $\mathrm{PT}=0.08$ ) to moderate ( $\mathrm{PT}=2.58$ ) bioactivity. In case of the 1 series compounds, viz. $\mathbf{1 a}, \mathbf{1 b}, \mathbf{1 c}$ etc. the methoxy group on the aromatic ring falls outside the favorable area of the parallelepiped, thus showing poor (max $\mathrm{PT}=1.17$ ) bioactivity. For compounds of the Xa or Xd series, the
terminal methyl group on the ethyl or isopropyl moieties falls in the disfavored region on the critical amidic nitrogen side, thus consistently exhibiting poor ( $\mathrm{PT}=0.08$ ) to moderate ( $\mathrm{PT}=2.0$ ) with the exceptions of $\mathbf{4 d}$ (2.67) and 3d (3.0).

The rest of the compounds that have relatively favorable 3D-spatial disposition with regard to the parallelepiped show bioactivities of 3.00 or larger with the exceptions of 2c $(\mathrm{PT}=2.83)$, $\mathbf{6 b}(\mathrm{PT}=2.83)$ and 7b $(\mathrm{PT}=2.17)$.

The other significant ( $\mathrm{DSP}>1 \%$ ) QSAR model A coefficients are Energy (conformational energy) with a negative $4.9 \%$ contribution, ADME_Absorption_T2_2D with a positive $3.3 \%$ contribution and ADME_BBB_ Level_2D with a negative $2 \%$ contribution. Our QSAR study showed poor correlation between molar refractivity (MR and MolRef) and repellency, unlike that reported by Suryanarayana et al. [41].

## QSAR Models A-G Validation

## Internal validation tests

Internal validation (cross-validation) tests of selected QSAR models (see Table 11) were performed at three levels. All models showed $q^{2}{ }_{\text {LOO }}>0.983$ for the leave-oneout cross-validation tests. For the leave-10\%-out (leave-three-out) cross-validation tests, four models viz. A, C, D
and E showed $q^{2}{ }_{\mathrm{L} 10 \mathrm{O}}>0.98$, whereas models $\mathrm{B}, \mathrm{F}$ and G showed $q^{2}{ }_{\text {L10O }}$ values of $0.978,0.976$ and 0.955 , respectively. Five models viz. A-E showed $q^{2}{ }_{\text {L20O }}>0.96$ for the leave-20\%-out (leave-six-out) cross-validation tests, while models $F$ and $G$ showed $q^{2}$ L200 values of 0.705 and 0.884 respectively.

## QSAR model validation by randomization tests

It is known that even with large number of observations and fewer terms, QSAR models can be poorly predictive. Thus, with fewer observations (in this study thirty compounds) and many more terms (in this study one hundred and twenty seven descriptors down selected to thirty), QSAR models are prone to chance correlation. In the randomization test, the dependent variables (bioactivity values) are randomly reassigned to different compounds and new regression models are recomputed. This process is repeated several times. If the statistical data of these randomized models is comparable to the QSAR model developed, then the QSAR model developed is not predictive and the number of observations is insufficient. We performed two sets of randomization tests of ninety-nine trials each at 99\% confidence level for all QSAR models A-G. The results of the randomization tests are shown in Table 11. The best mean random $r$ value obtained for models $\mathrm{A}-\mathrm{F}$ is 0.133 ( $r^{2}=0.018$ ) and model G is $0.240\left(r^{2}=0.058\right)$. The best

Table 11 Validation tests results six (A-F) models built using selected 30 descriptors and (G) Model built using 127 descriptors

## Internal validation tests

| Validation tests | Model \# | A | B | C | D | E | F | G |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Leave-one-out | $q^{2}$ | 0.989 | 0.988 | 0.991 | 0.989 | 0.991 | 0.988 | 0.983 |
|  | PRESS | 0.759 | 0.801 | 0.631 | 0.762 | 0.593 | 0.795 | 1.127 |
| Leave-10\%-out | $q^{2}$ | 0.980 | 0.978 | 0.991 | 0.988 | 0.984 | 0.976 | 0.955 |
|  | PRESS | 1.329 | 1.469 | 0.586 | 0.805 | 1.089 | 1.644 | 3.051 |
| Leave-20\%-out | $q^{2}$ | 0.963 | 0.977 | 0.978 | 0.978 | 0.981 | 0.705 | 0.884 |
|  | PRESS | 2.552 | 1.570 | 1.472 | 1.450 | 1.280 | 20.110 | 7.933 |
| Randomization tests <br> 99 trails at 99\% confidence level <br> $((\#$ Random $r)>($ non-Random $r))=0$ |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| $r$ from non-Random |  | 0.995 | 0.995 | 0.995 | 0.995 | 0.996 | 0.994 | 0.992 |
| Test 1 | Mean value of $r$ from random trial | 0.071 | 0.111 | 0.100 | 0.113 | 0.112 | 0.133 | 0.240 |
|  | Std deviation of random trial | 0.192 | 0.248 | 0.233 | 0.244 | 0.226 | 0.253 | 0.311 |
| Test 2 | Mean value of $r$ from random trial | 0.087 | 0.103 | 0.110 | 0.118 | 0.105 | 0.131 | 0.225 |
|  | Std deviation of random trial | 0.219 | 0.222 | 0.248 | 0.255 | 0.233 | 0.257 | 0.312 |
| External validation tests |  |  |  |  |  |  |  |  |
| All 10 test set compounds | Predictive $r^{2}$ | 0.335 | 0.333 | 0.334 | 0.319 | 0.333 | 0.334 | 0.228 |
|  | $s(y)$ | 1.321 | 1.321 | 1.330 | 1.326 | 1.333 | 1.319 | 1.251 |
|  | $F$-value | 4.028 | 4.002 | 4.012 | 3.743 | 3.996 | 4.007 | 2.361 |
| 8 compounds (w/o compounds $1 \mathbf{1 a}$ and 7d) | Predictive $r^{2}$ | 0.845 | 0.663 | 0.669 | 0.651 | 0.676 | 0.666 | 0.219 |
|  | $s(y)$ | 0.242 | 0.418 | 0.416 | 0.410 | 0.410 | 0.415 | 0.608 |
|  | $F$-value | 32.764 | 11.789 | 12.127 | 11.208 | 12.520 | 11.960 | 1.684 |

random $r$ value possible (based on the standard deviation) is about $0.4\left(r^{2}=0.16\right)$ for models $\mathrm{A}-\mathrm{F}$ and about 0.55 ( $r^{2}=0.303$ ) for model G. These correlation-coefficient values are far lower than the non-Random $r$ values of 0.995 ( $r^{2}=0.99$ ), thus indicating that the QSAR models A-G are not obtained by chance.

## External validation tests

The selection of bioactive conformation of the test compounds for activity prediction is challenging. Bhonsle et al. [28] have reported the use of a predictive $r^{2}$ approach to demonstrate that there always is a test compound conformer within the energy range of 5 kcal $\mathrm{mol}^{-1}$ of the global minima that accurately predicts the bioactivity. We used the same predictive $r^{2}$ approach to discover the best conformer that predicted the bioactivity most accurately.

On the test set of ten compounds, all the QSAR models A-F showed predictive $r^{2}$ values of 0.33 and variance $s(y)$ values of 1.3 , while model G showed predictive $r^{2}$ and $s(y)$ values of 0.23 and 1.25 , respectively. Two low-activity test compounds viz. 1a $(\mathrm{PT}=0.08)$ and $\mathbf{7 d}(\mathrm{PT}=1.0)$ were consistently found to be the outliers. The poor activity of 1a and $7 \mathbf{d}$ could be ascribed to their low vapor pressures of 0.0062 and 0.0014 at $30^{\circ} \mathrm{C}$ as compared to that of DEET (0.026). Thus, justifiably, removing them from the test set models B-F gave good predictive $r^{2}$ values of 0.65 to 0.67 and $\mathrm{s}(\mathrm{y})$ values of about 0.41 , while model A gave the best predictive $r^{2}$ value of 0.845 with the smallest variance $s(y)$ value of 0.242 . Model $G$ performed poorly on the eight test compounds with predictive $r^{2}$ and $s(y)$ values of 0.219 and 0.608 , respectively. The $F$-values for the ten test compounds regression for all models $\mathrm{A}-\mathrm{F}$ are between 3.7 and 4.0. The reported [75] $F$-values for $\alpha=0.10$ ( $90 \%$ confidence level) for ten observations is 3.46 . Thus, the predictions of all the models $\mathrm{A}-\mathrm{F}$ on the ten test compounds are statistically significant with less than $10 \%$ probability that the null hypothesis is true. The reported [75] $F$-values for $\alpha=0.025$ ( $97.5 \%$ confidence level) for eight observations is 8.81 . The predictions of all the models A-F on the eight test compounds are statistically significant with confidence levels larger than $98 \%$ for $F$-values ranging from 11.2 to 32.7 . The prediction correlation of model A is the strongest with $F$-values of 32.8 , which is within the $99.5 \%$ confidence level based on the reported $F$-value for $\alpha=0.005$ ( $99.5 \%$ confidence level) of 18.63 . The $F$-values for model $G$ of 2.4 and 1.7 for the ten and eight set compounds, respectively, indicate that the prediction regression is also less than $90 \%$ statistically significant. The best conformer numbers, predicted bioactivities and the PPE for QSAR Model A on the test set compounds are shown in Table 12.

Table 12 Best QSAR Model A external test set validation results

| Compd <br> $\#$ | Actual <br> bioactivity | Best <br> available <br> conformer <br> number | Best <br> conformer <br> predicted <br> bioactivity | Percent error in best <br> conformer <br> predicted <br> bioactivity=(BA- <br> PredBA) |
| :--- | :--- | :--- | :--- | :--- |
|  |  |  |  |  |
| $\mathbf{1 a}$ | 0.08 | 19 | -1.781 | 2325.64 |
| 2d | 0.50 | 1 | 1.782 | 256.48 |
| 3b | 1.67 | 1 | 1.964 | 17.62 |
| $\mathbf{3 e}$ | 3.00 | 0 | 2.810 | 6.35 |
| 4c | 5.00 | 12 | 3.585 | 28.30 |
| 4d | 2.67 | 17 | 2.663 | 0.28 |
| $\mathbf{5 d}$ | 1.00 | 19 | 2.267 | 126.67 |
| 6d | 1.08 | 11 | 2.362 | 118.72 |
| 7b | 2.17 | 5 | 2.154 | 0.72 |
| 7d | 1.00 | 18 | 3.749 | 274.89 |

GFA and G/PLS models based on mined bioactive conformers of QSAR model A

The GFA- and G/PLS-based QSAR models built using the global minimum conformers and the selected pool of thirty descriptors showed poor predictive performance vis-à-vis models A-G (see Tables 3 and 11). In order to investigate if the selected conformers in QSAR model A are indeed the bioactive conformers, we built GFA- and G/PLS-QSAR models based on these conformers using the selected pool of thirty descriptors. The statistical data of the GFA and G/ PLS models is shown in Table 13. The GFA- and G/PLSmodels showed non-validated $r^{2}$ of 0.989 and 0.991 , respectively, and excellent (regression-only) cross-validated $q^{2}$ LOO of 0.949 and 0.981 , respectively. Both models showed superior cross-validated $q^{2}$ on all the internal validation tests for leave-one-out, leave-10\%-out and leave- $20 \%$-out of 0.924 or larger.

The GFA model showed good $q_{\text {L200 }}^{2}$ of 0.723 . The randomization tests showed the best random mean $r$ values for the GFA and G/PLS models as $0.503\left(r^{2}=0.253\right)$ and $0.814\left(r^{2}=0.663\right)$, with the possible approximate random $r$ values (based on the standard deviation of random trials) of $0.665\left(r^{2}=0.442\right)$ and $0.885\left(r^{2}=0.783\right)$, respectively. In the external validation tests on the test set of ten compounds, both the GFA- and G/PLS-models exhibited poor predictive $r^{2}$ and variance $s(y)$ values of 0.375 and 1.335 for the GFAmodel and 0.363 and 1.302 for the G/PLS-model. The $F$-value of 4.803 and 4.551 compared to 3.46 (at $\alpha=0.10$ or $90 \%$ confidence level) indicates that the prediction correlation is statistically significant within the $90 \%$ confidence level. However, eliminating the usual outlier compounds, 1a and $7 \mathbf{d}$, from the test set furnished extraordinary predictive $r^{2}$ and $s(y)$ values of 0.973 and 0.126 , respectively, for the GFA-model, with a very strong $F$-value of 214.7 (reported [75] $F$-critical value at $\alpha=0.001$ for the $99.9 \%$ confidence

Table 13 Statistical data of GFA and G/PLS Models using Bioactive Conformer from QSAR Model A

level is 35.51 ) indicating a highly statistically significant correlation within the $99.9 \%$ confidence level. The G/PLSmodel shows fair predictive $r^{2}$ and $s(y)$ values on the eightcompound test set of 0.687 and 0.432 , respectively, with a good $F$-value of 13.189 (reported [75] $F$-critical value at $\alpha=0.025$ for $97.5 \%$ confidence level is 8.81 ).

The plots of actual vs. predicted bioactivity for model A, the GFA-model and the G/PLS-model are shown in Fig. 10.

The best activity-predicting conformer numbers for all the models are shown in Table 14. It is noteworthy that among the ten test-set compounds, six compounds have the same conformer number as the best activity predictors. Of the remaining four compounds, three compounds have only two conformers as best predictors. Only compound 4d has three different best predicting conformers for the three models. An overlay of the best predicting conformers of $\mathbf{7 b}$ show near perfect overlap, the $\mathbf{3 b}$ conformers show within $30^{\circ}$ angle separation and 4 d conformers show $40^{\circ}$ angle separation of the alkyl group on the amidic N (see Fig. 9).

The descriptor significance percentage (DSP) computation for the GFA and G/PLS is shown in Table 15. The GFA- and G/PLS-models are in $94 \%$ agreement with each other, except on descriptor Atype_H_47, where the GFAmodel shows a negative $4 \%$ contribution and the G/PLSmodel shows a positive $3.6 \%$ contribution. The GFA-model is in agreement with model A, having $80 \%$ concurrence in positive and negative DSP effects, while the G/PLS-model concurs with the model A on $95 \%$ of the DSP values. The G/PLS-model shows disagreement with model A on the descriptor Jurs-FPSA-1 with a negative $5 \%$ contribution, while model A has a positive $2.3 \%$ contribution. The GFAmodel showed disagreement with model A on three descriptors, viz. Atype_H_47, ADME_Absorption_T2_2D and Jurs-FPSA-1 with negative $4 \%$, negative $2.9 \%$ and negative $14.2 \%$ contributions, while model A exhibited positive $3.5 \%$, positive $3.3 \%$ and positive $2.3 \%$, respectively. The first two descriptors, Atype_H_47 and ADME_Absorption_T2_2D relate to hydrophobicity/lipophilicity, while the latter two ADME_Absorption_T2_2D and Jurs-FPSA- 1 relate to polar surfaces in the repellent


Fig. 10 Plots of actual bioactivity vs. predicted bioactivity for model A, GFA model and G/PLS

Table 14 Best activity predicting conformer numbers

| Test compound | QSAR Model \# A | GFA model | G/PLS model |
| :--- | :--- | :--- | :--- |
| $\mathbf{1 a}$ | 19 | 13 | 19 |
| $\mathbf{2 d}$ | 1 | 1 | 1 |
| $\mathbf{3 b}$ | 1 | 17 | 17 |
| $\mathbf{3 e}$ | 0 | 0 | 0 |
| $\mathbf{4 c}$ | 12 | 12 | 12 |
| $\mathbf{4 d}$ | 17 | 14 | 9 |
| $\mathbf{5 d}$ | 19 | 19 | 19 |
| $\mathbf{6 d}$ | 11 | 11 | 11 |
| $\mathbf{7 b}$ | 5 | 21 | 5 |
| $\mathbf{7 d}$ | 18 | 18 | 18 |

molecules. As discussed in the previous section, the four aspects involved in the first two steps of the mechanism of action of the repellents are hydrophobicity/lipophilicity, positively charged surface area, positively and negatively charge separation or dipole and lastly molecular shape. Both the G/PLS and model A indicate that the soft or diffused positively charged surface on the repellent molecules contribute about 17 to $22 \%$ to the bioactivity, whereas the GFA-model suggests that this effect does not contribute positively to the bioactivity. The GFA-model disagrees with the other two models on the contribution towards the hydrophobicity/lipophilicity aspect from the descriptors Jurs-RASA and Atype_H_47. The disagreements among the three models could be ascribed to the significance each model associates to each of the steps in the mechanism of

Table 15 DSP computation for GFA and G/PLS Models built with conformers of model A

| Descriptor | MVD | GFA |  |  | G/PLS |  |  | PLS <br> DSP |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | QEC | CtoBA | DSP | QEC | CtoBA | DSP |  |
| Jurs-RASA | 0.882 | 25.501 | 22.484 | 34.887 | 13.777 | 12.147 | 26.360 | 25.038 |
| Jurs-FPSA-3 | 0.074 | 42.501 | 3.142 | 4.876 | 80.961 | 5.986 | 12.989 | 11.161 |
| JX | 2.527 | 1.663 | 4.202 | 6.520 | 1.980 | 5.004 | 10.859 | 8.690 |
| ADME_Solubility_Level | 3.100 | -1.081 | -3.350 | -5.198 | -0.781 | -2.420 | -5.252 | -8.514 |
| Shadow-Xlength | 11.888 | -0.589 | -7.006 | -10.871 | -0.451 | -5.365 | -11.641 | -7.703 |
| Kappa-3-AM | 2.568 | 1.025 | 2.632 | 4.084 | 0.810 | 2.081 | 4.517 | 7.577 |
| Energy | 51.357 | -0.066 | -3.410 | -5.291 | -0.067 | -3.433 | -7.451 | -4.912 |
| Atype_H_47 | 7.933 | -0.331 | -2.627 | -4.077 | 0.209 | 1.655 | 3.591 | 3.530 |
| DIPOLE_MOPAC | 3.553 | 0.665 | 2.364 | 3.667 | 0.408 | 1.448 | 3.142 | 3.490 |
| ADME_Absorption_T2_2D | 2.736 | -0.671 | -1.835 | -2.848 | - | - | - | 3.344 |
| Shadow-nu | 1.909 | - | - | - | - | - | - | -2.301 |
| Jurs-FPSA-1 | 0.770 | -11.853 | -9.130 | -14.167 | -3.248 | -2.502 | -5.429 | 2.252 |
| ADME_BBB_Level_2D | 1.300 | - | - | - | -0.762 | -0.991 | -2.150 | -2.034 |
| Jurs-DPSA-3 - | 50.052 | - | - | - | -0.049 | -2.472 | -5.364 | -1.628 |
| Shadow-XY | 59.513 | - | - | - | - | - | - | -1.109 |
| Fh2o | -4.866 | - | - | - | - | - | - | -1.073 |
| PMI-mag | 324.800 | - | - | - | - | - | - | -0.993 |
| Shadow-Zlength | 6.306 | - | - | - | - | - | - | -0.815 |
| Density | 1.004 | - | - | - | - | - | - | 0.711 |
| Jurs-RPCS | 0.488 | - | - | - | - | - | - | 0.595 |
| S_ssNH | 0.642 | -1.766 | -1.134 | -1.760 | -0.598 | $-0.384$ | -0.833 | -0.536 |
| Jurs-FNSA-2 | -0.438 | - | - | - | - | - | - | -0.528 |
| S_aasC | 1.148 | -0.294 | -0.337 | -0.524 | -0.169 | -0.194 | -0.421 | -0.501 |
| Jurs-DPSA-2 | 808.217 | - | - | - | - | - | - | -0.298 |
| S_ssO | 1.394 | - | - | - | - | - | - | 0.172 |
| ADME_BBB_2D | 0.103 | -5.604 | $-0.580$ | -0.900 | - | - | - | -0.160 |
| S_dssC | 0.114 | - | - | - | - | - | - | -0.138 |
| HF_MOPAC | -11.390 | 0.019 | -0.213 | -0.331 | - | - | - | -0.107 |
| Atype_C_5 | 0.533 | - | - | - | - | - | - | -0.090 |
| LUMO_MOPAC | 0.094 | - | - | - | - | - | - | 0.000 |

QEC: QSAR Equation Coefficient values
MVD: Mean value of descriptors of all the training set compounds ( $\sum$ descriptor_value/30)
CtoBA: Contribution of the descriptor to bioactivity (QEC*MVD)
DSP: Descriptor Significance Percentage (CtoBA*100/ $\sum \mathrm{abs}(\mathrm{CtoBA})$ )
action towards the overall bioactivity. The GFA-model suggests that both hydrophobicity/lipophilicity and positively charged surface area play lesser roles in the overall bioactivity, while both the G/PLS-model and model A suggest otherwise. For the positively charged surface area property, the G/PLS-model suggests that, although this property does play a role in the overall bioactivity, the descriptor Jurs-FPSA-1 does not contribute positively, unlike Jurs-FPSA-3 and JX. Model A suggests that all Jurs-FPSA-3, JX and jurs-FPSA-1 contribute positively towards this property.

QSAR model comparison with earlier reported model developed using CATALYST

The QSAR model A was found to be qualitatively consistent with the earlier reported pharmacophore model. The CATA-

LYST based protocol reported earlier [44] resulted in the generation of ten pharmacophores. The correlation coefficients were found to range from 0.91 to 0.87 for six of the ten models. The total costs of the pharmacophores varied over a narrow range ( 45 to 51 ) and the difference between the fixed cost and the null cost was 71 bits, satisfying the acceptable range as recommended in the cost analysis of the CATALYST procedure [56]. A difference of 71 bits between the fixed and the null cost clearly indicates the robustness of the correlation. Moreover, as the cost difference between the first to the tenth hypothesis and the null hypothesis was found to be between 66 and 60 bits, it could be expected that for all these hypotheses there is a $80-92 \%$ chance of representing a true correlation in the data. The Fischer randomization test as implemented in the CatScramble module of CATALYST gave nineteen random spreadsheets from the training set. Sixteen of the randomized models

Fig. 11 CATALYST based pharmacophore model for insect repellency


H-bond
acceptor
generated required a total cost value lower than the model under investigation, indicating an approximately $85 \%$ confidence level of our pharmacophore model.

Significantly, the best pharmacophore characterized by two hydrophobic aliphatic functions, one aromatic ring function and one hydrogen-bond acceptor function (Fig. 11) is also statistically the most relevant pharmacophore.

A total of fifteen compounds were selected for the mapping experiments with the reported pharmacophore. The five most active ( $\mathrm{PT}>4.0$ ) compounds selected were $\mathbf{2 b}, \mathbf{4 c}, \mathbf{5 b}, \mathbf{7 c}$ and $\mathbf{8 c}$. The five moderately active $(4.0>\mathrm{PT}>2.8)$ compounds selected were $\mathbf{3 d}$, $\mathbf{3 e}, \mathbf{5 c}, \mathbf{6 b}$ and $\mathbf{8 b}$. Lastly the five inactive ( $\mathrm{PT}<0.5$ ) compounds selected were 1a, 2a, 2d, 6a and 8a. The conformers selected for mapping were the same ones as those selected for the QSAR model A. The conformers of the most active compounds mapped all the functional features of the best hypothesis with high scores, whereas the less active compounds mapped fewer of the features.

## Conclusion

A highly predictive QSAR model has been built for benzamides and benzylamides employing a semi-automated quasi multi-way PLS approach. The QSAR model concurs
with the reported physicochemical properties like lipophilicity, molecular shape and size and correlation to repellency bioactivity. The novel methodology of gradual and stepwise refinement of successive generation QSAR models results in selection of bioactive conformers. The selected bioactive conformers generate far superior GFA and G/PLS QSAR models than those obtained from the global minimum conformers. The poses/shapes of the selected bioactive conformers provide valuable insight into the mechanism of action of the insect repellents. The phenyl, benzyl or cyclohexyl moieties on the carbonyl carbon are proposed to bind to the odorant binding proteins, whereas the alkyl and cycloalkyl moieties on the amidic nitrogen are suggested to interact with the GPCRs on the insect neuron cells. Since the identity of the target for arthropod repellent activity remains unknown, these QSAR models and the related analysis should aid in the design of well-tolerated, target-specific arthropod-repellent agents. Effective and efficient use of use of Tcl-based Cerius2 scripts is demonstrated in developing highly predictive QSAR models.

Acknowledgements This research was performed while one of the authors (JBB) held a National Research Council Research Associateship Award at Walter Reed Army Institute of Research. The authors gratefully acknowledge funding from the U.S. Department of Defense Health Program. This work was first presented as a poster presentation
at the Fourth Indo-US Workshop on Mathematical Chemistry, Pune, India; January 2005. We are grateful to the referees for their helpful comments and suggestions. We gratefully acknowledge the technical help (Drs. Mehl, Shah and Salaniwal), customer support (Mr. Fankhanel and Dr. Robinson) of Accelrys, Inc. and help with statistics from Mr. Charles White, Senior Biostatistician, WRAIR. JBB is thankful to Dr. Donald Huddler for help in manuscript preparation.

## References

1. Hansch C (1969) Acc Chem Res 2:232-239
2. Cramer RD III, Patterson DE, Bunce JD (1988) J Am Chem Soc 110:5959-5967
3. Hopfinger AJ, Burke BJ (1990) In: Johnson MA, Maggiora GM (eds) Molecular shape analysis: a formalism to quantitatively establish spatial molecular similarity. Wiley, New York, pp 173209
4. Klebe G (1998) Perspectives in drug discovery and design. 12/13/ 14:87-104
5. Jain AN, Dietterich TG, Lathrop RH, Chapman D, Critchlow RE Jr, Bauer BE, Webster TA, Lozano-Perez T (1994) J Comput-Aid Mol Des 8:635-652
6. Doweyko AM (1991) J Math Chem 7:273-285
7. Wiener H (1947) J Am Chem Soc 69:17-20
8. Bonchev D (1983) Chemometrics series, vol 5. Information theoretic indices for characterization of chemical structures, p 249
9. Hosoya H (1971) Bull Chem Soc Jpn 44:2332-2339
10. Kier LB, Hall LH (1976) Medicinal chemistry, vol 14. Molecular connectivity in chemistry and drug research. Academic, New York, p 257
11. Kier LB (1985) Quant Struct-Act Relat 4:109-116
12. Kier LB, Hall LH, Frazer JW (1991) J Math Chem 7:229-241
13. Balaban AT (1982) Chem Phys Lett 89:399-404
14. Bonchev D, Mekenyan O, Trinajstic N (1981) J Comput Chem 2:127-148
15. Marsili M, Gasteiger J (1981) Croat Chem Acta 53:601-614
16. Rohrbaugh RH, Jurs PC (1987) Anal Chim Acta 199:99-109
17. Stanton DT, Jurs PC (1990) Anal Chem 62:2323-2329
18. Kharkar PS, Desai B, Gaveria H, Varu B, Loriya R, Naliapara Y, Shah A, Kulkarni VM (2002) J Med Chem 45:4858-4867
19. Drew MGB, Wilden GRH, Spillane WJ, Walsh RM, Ryder CA, Simmie JM (1998) J Agricult Food Chem 46:3016-3026
20. Hirashima A, Rafaeli A, Gileadi C, Kuwano E (1999) Bioorg Med Chem 7:2621-2628
21. Hasegawa K, Arakawa M, Funatsu K (2000) Chemom Intell Lab Syst 50:253-261
22. Hopfinger AJ, Wang S, Tokarski JS, Jin B, Albuquerque M, Madhav PJ, Duraiswami C (1997) J Am Chem Soc 119:1050910524
23. Hasegawa K, Arakawa M, Funatsu K (2003) Comput Biol Chem 27:211-216
24. Vedani A, McMasters DR, Dobler M (2000) Quant Struct-Act Relat 19:149-161
25. Appell M, Dunn WJ, Reith MEA, Miller L, Flippen-Anderson JL (2002) Bioorg Med Chem 10:1197-1206
26. Xiao Y-D, Hammond PS, Harris R, Schmitt JD, Klucik J (2004) J Med Chem 47:6831-6839
27. Sulea T, Kurunczi L, Oprea TI, Simon Z (1998) J Comput-Aid Mol Des 12:133-146
28. Bhonsle JB, Wang Z-X, Tamamura H, Fujii N, Peiper SC, Trent JO (2005) QSAR \& Combinat Sci 24:620-630
29. Accelrys Software Inc (2005) Cerius2 Modeling Environment, Release 4.9. San Diego, CA, USA
30. Brewste D (2001) BioMed J 323:289
31. Bock GR, Cardew G (1996) Symposium on Olfaction in Mosquito-Host Interactions, held in Collaboration with the World Health Organization at the Ciba Foundation, London, 31 October2 November 1995. In: Ciba Found Symp 200. p 331
32. Davis EE, Bowen MF (1994) J Am Mosquito Control 10:316-325
33. Davis EE (1985) J Med Entomol 22:237-243
34. McIver SB (1981) J Med Entomol 18:357-361
35. Justice RW, Biessmann H, Walter MF, Dimitratos SD, Woods DF (2003) BioEssays 25:1011-1020
36. Rao SS, Rao KM, Ramachandran PK (1988) J Sci \& Indust Res 47:722-735
37. McGovern TP, Schreck CE, Jackson J (1984) Mosquito News 44:11-16
38. Skinner WA, Johnson HL (1980) Med Chem 11:277-305
39. Sugawara R, Tominaga Y, Suzuki T (1977) Insect Biochem 7:483-485
40. Wright RH (1975) Sci Am 233:104-111
41. Suryanarayana MVS, Pandey KS, Prakash S, Raghuveeran CD, Dangi RS, Swami RV, Rao KM (1991) J Pharm Sci 80:10551057
42. Ma D, Bhattacharjee AK, Gupta RK, Karle JM (1999) Am J Trop Med Hyg 60:1-6
43. Bhattacharjee AK, Gupta RK, Ma D, Karle JM (2000) J Mol Recognit 13:213-220
44. Bhattacharjee AK, Dheranetra W, Nichols DA, Gupta RK (2005) QSAR \& Combinat Sci 24:593-602
45. Marsili M, Gasteiger J (1981) Stud Phys Theor Chem 16:56-67
46. Mayo SL, Olafson BD, Goddard WAI (1990) J Phys Chem 94:8897-8909
47. Golbraikh A, Tropsha A (2002) Molecular Diversity 5:231-243
48. Accelrys Software Inc (2005) Performing a conformational analysis. In: Cerius2, version 4.10L. Conformational Search \& Analysis Manual, vol San Diego, CA, USA, p 49
49. Bhonsle JB (2005) Cerius2_ConfSrchAndAnalysis
50. Accelrys Software Inc (2005) Genetic Function Approximation. In: Cerius2, version 4.10. QSAR Manual, vol San Diego, CA, p 237
51. Accelrys Software Inc (2005) In: Cerius2, version 4.10. QSAR Manual, vol San Diego, CA, p 34
52. Accelrys Software Inc (2005) Theory: Statistical Methods. In: Cerius2, version 4.10. QSAR Manual, vol San Diego, CA, p 33
53. Bro R (1996) J Chemomet 10:47-61
54. Hasegawa K, Arakawa M, Funatsu K (1999) Chemom Intell Lab Syst 47:33-40
55. Bhonsle JB (2005) Cerius2_QSARModel_computationScript
56. Accelrys Software Inc (2005) Catalyst, verrsion 4.10. San Diego, California, USA
57. Bhonsle JB (2005) Cerius2_confAlignmentScript
58. Ghose AK, Crippen GM (1986) J Comput Chem 7:565-577
59. Ghose AK, Crippen GM (1987) J Chem Inf Comput Sci 27:21-35
60. Kier LB, Hall LH (1992) The electrotopological state index: an atom-centered index for QSAR. Academic, London, UK, pp 205
61. Hall LH, Kier LB (1991) Rev Comput Chem 2:367-422
62. Hill TL (1960) An introduction to statistical thermodynamics. Addison-Wesley Publishing Co, Reading, Massachusetts, p 508
63. Dewar MJS, Thiel W (1977) J Am Chem Soc 99:4907-4917
64. Richon AB , Young SS (1997) An introduction to QSAR methodology. Network Science Corporation, Saluda, NC
65. L'Heureux PJ, Carreau J, Bengio Y, Delalleau O, Yue SY (2004) J Comput-Aid Mol Des 18:475-482
66. Olah M, Bologa C, Oprea TI (2004) J Comput-Aid Mol Des 18:437-449
67. Sutter JM, Dixon SL, Jurs PC (1995) J Chem Inf Comput Sci 35:7784
68. Zheng W, Tropsha A (2000) J Chem Inf Comput Sci 40:185-194
69. Yao SW, Lopes VHC, Fernandez F, Garcia-Mera X, Morales M, Rodríguez-Borges JE, Cordeiro MNDS (2003) Bioorganic \& Medicinal Chemistry 11:4999-5006
70. Tripos Inc (2003) Sybyl Molecular Modeling System, version 6.9.1. St. Louis, MO, USA
71. Johnson HL, Tsakotellis P, Skinner WA, Skidmore D, Maibach HI (1971) J Pharm Sci 60:84-89
72. Sandler BH, Nikonova L, Leal WS, Clardy J (2000) Chem Biol 7:143-151
73. McKenna MP, Hekmat-Scafe DS, Gaines P, Carlson JR (1994) J Biol Chem 269:16340-16347
74. Pikielny CW, Hasan G, Rouyer F, Rosbash M (1994) Neuron 12:35-49
75. Beyer WH (1985) CRC Handbook of Tables for Probability and Statistics, 2nd edn. CRC Press Inc, Boca Raton, FL, pp 305-310

[^0]:    J. B. Bhonsle $(\boxtimes) \cdot$ A. K. Bhattacharjee

    Department of Medicinal Chemistry,
    Division of Experimental Therapeutics,
    Walter Reed Army Institute of Research, 503 Robert Grant Avenue,
    Silver Springs, MD 20910, USA
    e-mail: Jayendra.Bhonsle@na.amedd.army.mil
    A. K. Bhattacharjee
    e-mail: Apurba.Bhattacharjee@na.amedd.army.mil
    R. K. Gupta

    Office of the Director, Research, Plans and Programs, Ft. Detrick, MD 21702, USA

[^1]:    $P T=$ Protection Time; $V P=$ Vapor Pressure @ $30{ }^{\circ} \mathrm{C}$

[^2]:    QEC: QSAR Model A Equation Coefficient values
    MVD: Mean value of descriptors of all training compounds = ( $\sum$ descriptor_value/30)
    CtoBA: Contribution of the descriptor to bioactivity $=\left(\mathrm{QEC}^{*} \mathrm{MVD}\right)$
    DSP: Descriptor Significance Percentage $=\left(\right.$ CtoBA ${ }^{*} 100 / \sum$ abs $\left.(C t o B A)\right)$

